

# Health Economics, Outcomes & Epidemiology

PUBLISHED RESEARCH AND PRESENTATIONS





# Health Economics, Outcomes & Epidemiology

PUBLISHED RESEARCH AND PRESENTATIONS

## **A COMPENDIUM OF OUR RESEARCH**

Health outcomes research is playing an increasingly important role in pharmaceutical development as new products enter competitive markets and face demands for economic evidence, safety, and efficacy. A clear and early understanding of value is critical to commercial success, and requires companies to have capabilities in health economics and associated disciplines of epidemiology, biostatistics, outcomes research, and pharmacoeconomics in place for ready use across their customers and therapeutic areas.

For three decades, Analysis Group has been distinguished by a unique combination of expertise in health economics, outcomes research, epidemiology, biostatistics, and health policy. Our outcomes research has resulted in thought leadership and a robust record of publications and presentations across the leading medical, outcomes, and health economics journals and conferences, covering a range of clinical and methodological areas. This compendium includes published manuscripts as well as abstracts through April 2011.

For more information on our research activities and health care consulting practice, please visit our website, [www.analysisgroup.com](http://www.analysisgroup.com).





**CONTENTS**

ANEMIA	1
CARDIOVASCULAR DISEASE	3
DERMATOLOGY	5
DIABETES	8
ENDOCRINOLOGY	9
GASTROINTESTINAL DISORDERS	10
HEALTH ECONOMICS, POLICY, AND REGULATION	11
HEMATOLOGY	14
HOSPITALS	14
LONG-TERM CARE	15
MEDICATION COMPLIANCE	15
MENTAL HEALTH	16
MUSCULOSKELETAL DISEASE	21
NEPHROLOGY	21
NEUROLOGICAL DISORDERS	24
OBESITY, METABOLIC, AND NUTRITIONAL DISORDERS	25
ONCOLOGY	25
OVERACTIVE BLADDER	29
PAIN AND PRESCRIPTION OPIOIDS	29
PRICING AND REIMBURSEMENT	30
RESPIRATORY DISEASE	31
RHEUMATOLOGY	33
WOMEN'S HEALTH	34



## ANEMIA

### **Comment: the impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa**

*Publication:* Ann Pharmacother. 2010; 44(3):595; author reply 595-6.

*Authors:* Lefebvre P, Vekeman F, Crémieux PY

### **Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices**

*Publication:* Transfusion. 2009 Aug 28.

*Authors:* Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J

### **Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin**

*Publication:* Transfusion. 2009 May; 49(5):895-902. Epub 2009 Jan 21.

*Authors:* Vekeman F, Bookhart BK, White J, McKenzie RS, Duh MS, Piech CT, Lefebvre P

### **Drug utilization and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database**

*Publication:* J Med Econ. 2009 Mar; 12(1):1-8.

*Authors:* Vekeman F, McKenzie RS, Bookhart BK, Laliberté F, Duh MS, Tak Piech C, Lefebvre P

### **An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach**

*Publication:* Cancer. 2009 Feb 15; 115(4):706-15.

*Authors:* Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V

### **Anemia and the risk of injurious falls in a community-dwelling elderly population**

*Publication:* Drugs Aging. 2008; 25(4):325-34.

*Authors:* Duh MS, Mody SH, Lefebvre P, Woodman RC, Buteau S, Piech CT

### **Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis**

*Publication:* Ann Hematol. 2008 Mar.

*Authors:* Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S

### **Management of anaemia: a critical and systematic review of the cost-effectiveness of erythropoiesis-stimulating agents**

*Publication:* Pharmacoeconomics. 2008; 26(2):99-120.

*Authors:* Duh MS, Weiner JR, White LA, Lefebvre P, Greenberg PE

### **Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen**

*Publication:* Ann Pharmacother. 2008 Jan; 42(1):16-23.

*Authors:* Sikand H, Decter A, Greco T, Watson SH, Kang YJ, Mody SH, Piech CT, Duh MS, Naeem A

### **Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy?**

*Publication:* Hepatology. 2007 Jul; 46(1):283-4.

*Authors:* Wu WK, Duh MS, Lefebvre P

### **Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease**

*Publication:* J Am Soc Nephrol. 2006 Dec; 17(12):3497-502.

*Authors:* Lefebvre P, Duh MS, Buteau S, Bookhart B, Mody SH

### **Dose-conversion ratio for epoetin alfa and darbepoetin alfa in chemotherapy patients with anemia and cancer**

*Publication:* P&T. 2006 Oct; 31(10):594-603.

*Authors:* Gosselin A, McKenzie RS, Lefebvre P, Mody SH, Piech CT, Duh MS

### **Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of four observational studies**

*Publication:* Clin Ther. 2006 Oct; 28(10):1701-8.

*Authors:* Gosselin A, Pashos CL, Harley C, Mark TL, McKenzie RS

### **Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa**

*Publication:* Curr Med Res Opin. 2006 Oct; 22(10):1929-37.

*Authors:* Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Crémieux PY

**Impact and treatment of anemia in the elderly: clinical, epidemiological and economic perspectives**

*Publication:* Expert Rev Pharmacoeconomics Outcomes Res. 2006 Oct; 6(5):577-90.

*Authors:* Duh MS, Latypova A, Greenberg PE

**Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application**

*Publication:* J Oncol Pharm Practice. 2006 Sep; 12(3):165-78.

*Authors:* Crémieux PY, Vekeman F, Lefebvre P

**Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy**

*Publication:* J Support Oncol. 2006 May; 4(5):243-50.

*Authors:* Chu E, Einhorn LH, Lefebvre P

**Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia**

*Publication:* J Natl Compr Canc Netw. 2005 Nov; 3(6):807-16.

*Authors:* Campos SM, Duh MS, Lefebvre P, Rosberg J

**The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia**

*Publication:* Curr Med Res Opin. 2005 Oct; 21(10):1677-82.

*Authors:* Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Piech CT

**Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve**

*Publication:* Oncologist. 2005 Jun-Jul; 10(6):438-48.

*Authors:* Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ

**Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia**

*Publication:* Expert Rev Pharmacoeconomics Outcomes Res. 2005; 5(4): 383-395.

*Authors:* Duh MS, Mark TL

**Dose conversion and cost-effectiveness of erythropoietic therapies in chemotherapy-related anaemia: a meta-analysis**

*Publication:* Clin Drug Investig. 2005; 25(1):33-48.

*Authors:* Rosberg JH, Ben-Hamadi R, Crémieux PY, Fastenau JM, Piech CT

**Red blood cell transfusion and ventilator-associated pneumonia: a potential link?**

*Publication:* Crit Care Med. 2004; 32:666-674.

*Authors:* Shorr AF, Duh MS, Kelly KM, Kollef MH

**Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia**

*Publication:* J Manage Care Pharm. 2004 Nov-Dec; 10(6):531-7.

*Authors:* Crémieux PY, Fastenau JM, Kosicki G, Piech CT, Fendrick AM

**The CRIT study: anemia and blood transfusion in the critically ill—current clinical practice in the United States**

*Publication:* Crit Care Med. 2004 Jan; 32(1):39-52.

*Authors:* Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ

**Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy**

*Publication:* Cancer. 2002 Aug 15; 95(4):888-95.

*Authors:* Crawford J, Cella D, Cleeland CS, Crémieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA

**Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy**

*Publication:* J Clin Oncol. 2002 Jun 1; 20(11):2757-8.

*Authors:* Gabrielove JL, Sarokhan B, Crémieux PY

**Anemia-related costs for cancer patients**

*Publication:* J Managed Care Med. 2002; 6(1):20-8.

*Authors:* Barnett A, Crémieux PY, Fendrick AM, George M, Slavin MB

**Costs associated with anemia and cancer**

*Publication:* ONE: Oncology Economics. 2000; 1(11):1-7.

*Authors:* Crémieux PY, Gubens M, Holland M, Slavin MB

**Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anemia**

*Publication:* Pharmacoeconomics. 1999 Nov; 16(5 Pt 1):459-72.

*Authors:* Crémieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB

**Dosing pattern and cost comparison of epoetin alfa and darbepoetin alfa in chronic kidney disease and chemotherapy-induced anemia inpatients**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Lafeuille MH, Bailey RA, Senbetta M, McKenzie RS, Lefebvre P

**CARDIOVASCULAR DISEASE****Incremental third-party costs associated with COPD exacerbations: A retrospective claims analysis**

*Publication:* Med Econ. Epub 2011, April 18

*Authors:* Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S

**Copayment level, treatment persistence, and health care utilization in hypertension patients treated with single-pill combination therapy**

*Publication:* J Med Econ. 2011 Mar 30.

*Authors:* Yang W, Kahler KH, Fellers T, Orloff J, Chang J, Bensimon AG, Wu EQ, Fan CP, Yu AP

**Epidemiologic evaluation of cardiovascular risk in patients receiving milnacipran, venlafaxine, or amitriptyline: evidence from French health data**

*Publication:* Ann Pharmacother. 2011 Feb 8.

*Authors:* Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F, Guérin A, Boerstoel-Streefland M, Jiang W, Lefebvre P

**Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in U.S. patients with hypertension**

*Publication:* Am J Cardiovasc Drugs. 2011;11(1):21-32

*Authors:* Chang J, Yang W, Kahler KH, Fellers T, Orloff J, Bensimon AG, Yu AP, Fan CP, Wu EQ

**Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement**

*Publication:* Curr Med Res Opin. 2010 Sep; 26(9):2203-12

*Authors:* Chang J, Yang W, Fellers T, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ

**Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives**

*Publication:* Curr Med Res Opin. 2010 Sep; 26(9):2065-76.

*Authors:* Yang W, Chang J, Kahler KH, Fellers T, Orloff J, Wu EQ, Bensimon AG

**Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk**

*Publication:* Am J Ther. 2010 Aug 27.

*Authors:* Simpson RJ Jr, Signorovitch J, Ramakrishnan K, Ivanova J, Birnbaum H, Kuznik A

**Clinical outcomes and medical care costs among Medicare beneficiaries receiving therapy for peripheral arterial disease**

*Publication:* Ann Vasc Surg. 2010 Jul; 24(5):577-87.

*Authors:* Jaff MR, Cahill KE, Yu AP, Birnbaum HG, Engelhart LM

**Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension**

*Publication:* Curr Med Res Opin. 2010 Apr; 26(4):849-60

*Authors:* Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH

**Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs. simvastatin in an employed population**

*Publication:* Mayo Clin Proc. 2009 Dec; 84(12):1065-72.

*Authors:* Simpson RJ Jr, Signorovitch J, Birnbaum H, Ivanova J, Connolly C, Kidolezi Y, Kuznik A

**Costs associated with cardiovascular events in patients with hypertension in U.S. managed care settings**

*Publication:* J Am Soc Hypertens. 2009 Nov-Dec; 3(6):403-15

*Authors:* Duh MS, Fulcher NM, White LA, Jayawant SS, Ramamurthy P, Moyneur E, Ong SH

**Impact of single-photon emission computed tomography (SPECT) use after acute myocardial infarction (AMI) on cardiac procedure rates and hospital length of stay**

*Publication:* J Nucl Cardiol. 2007; 14(4):S115.

*Authors:* Wu EQ, Persson B, Beaulieu N, White L, Spalding J, Mahmarian JJ

**The economic impact of a partnership-measurement model of disease management: Improving Cardiovascular Outcomes in Nova Scotia (ICONS)**

*Publication:* Healthc Q. 2007; 10(2):38-46.

*Authors:* Crémieux PY, Fortin P, Meilleur MC, Montague T, Royer J

**Antihypertensive drugs: a perspective on the value of improved blood pressure control in the U.S.**

*Publication:* European Heart Journal Supplements. 2007; 9:B19-22.

*Authors:* Long G, Cutler DM, Berndt ER

**Productivity costs associated with cardiometabolic risk factor clusters in the United States**

*Publication:* Value Health. 2007 Nov–Dec; 10(6):443-50.

*Authors:* Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO

**Prevalence, referral patterns, testing, and surgery in aortic valve disease: leaving women and elderly patients behind?**

*Publication:* J Heart Valve Dis. 2007 Jul; 16(4):362-9.

*Authors:* Bach DS, Radeva JI, Birnbaum HG, Fournier AA, Tuttle EG

**Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S.**

*Publication:* Obesity. 2007 Feb; 15(2):511-21.

*Authors:* Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO

**The value of antihypertensive drugs: a perspective on medical innovation**

*Publication:* Health Affairs. 2007 Jan–Feb; 26(1):97-110.

*Authors:* Cutler DM, Long G, Berndt ER, Royer J, Fournier A, Sasser A, Crémieux PY

**Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States**

*Publication:* Stroke. 2006 Oct; 37(10):2567-72.

*Authors:* Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR

**Economic burden and co-morbidities of atrial fibrillation in a privately insured population**

*Publication:* Curr Med Res Opin. 2005 Oct; 21(10):1693-9.

*Authors:* Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W, Ruskin J

**Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population**

*Publication:* Womens Health Issues. 2005 May–Jun; 15(3):97-108.

*Authors:* Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D

**Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: estradiol transdermal system vs. oral estrogen-only hormone therapy**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P

**Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the U.S.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Korves C, Eldar-Lissai A, Rodermund D, Swallow KE, Cummings AK, Ariely R, Duh MS

**Chronic thromboembolic pulmonary hypertension (CTEPH): direct cost of illness in the U.S. privately insured population**

*Abstract:* Chest. 2010 Oct; 138(4):375A. American College of Chest Physicians CHEST 2010 Meeting, Vancouver, B.C., Canada, 30 Oct–4 Nov, (Poster)

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Schiller M, Joish VN, Williamson T

**Pulmonary arterial hypertension (PAH): direct cost of illness in the U.S. privately insured population**

*Abstract:* Chest. 2010 Oct; 138(4):376A. American College of Chest Physicians CHEST 2010 Meeting, Vancouver, B.C., Canada, 30 Oct–4 Nov, 2010 (Poster)  
*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Schiller M, Joish VN, Williamson T

**Persistence with nebivolol compared to other  $\beta$ -blockers in the treatment of hypertension: A retrospective claims analysis**

*Abstract:* American Heart Association, High Blood Pressure Research Conference 2010 Scientific Sessions, Washington D.C., 13-16 October, 2010 (Poster)  
*Authors:* Signorovitch J, Samuelson T, Ramakrishnan K, Marynchenko M, Blum SI, Ramasamy A, Wu EQ

**The epidemiology, treatment and care patterns, and medical resource utilization following hospitalization for heart failure**

*Abstract:* International Conference on Pharmacoepidemiology & Risk Management, Brighton, England, 19-22 August, 2010 (Poster)  
*Authors:* Korves C, McHale J, Lafeuille MH, Ariely R, Duh MS

**Hospitalization due to heart failure is associated with significant medical resource utilization and costs**

*Abstract:* Quality of Care and Outcomes Research (QCOR) in Cardiovascular Disease and Stroke 2010 Scientific Sessions, Washington D.C., 19-21 May, 2010 (Poster)  
*Authors:* Korves C, McHale J, Lafeuille MH, Ariely R, Duh MS

**Cardiovascular and economic outcomes following initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk**

*Abstract:* Quality of Care and Outcomes Research (QCOR) in Cardiovascular Disease and Stroke 2010 Scientific Sessions, Washington D.C., 19-21 May, 2010 (Poster)  
*Authors:* Simpson Jr R, Signorovitch J, Ramakrishnan K, Ivanova J, Birnbaum H, Kuznik A

**Blood pressure goal achievement among hypertension patients treated with valsartan-based single pill combination vs. ARB-based free combination in south central region**

*Abstract:* Value in Health. 2010 May; 13(3):A152. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)  
*Authors:* Chang JR, Yang W, Fellers TS, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ

**Compliance and health care utilization among patients with hypertension treated with single pill vs. free combination antihypertensive therapy: U.S. national and state level results from a claims database analysis**

*Abstract:* Value in Health. 2010 May; 13(3):A159. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)  
*Authors:* Yang W, Chang JR, Kahler KH, Fellers TS, Orloff J, Wu EQ, Bensimon AG, Fan CPS, Yu AP

**Aliskiren combined with angiotensin II-receptor blockers (ARB) resulted in better outcomes compared to ARB combined with angiotensin-converting enzyme inhibitors (ACEI): results from a claims database analysis**

*Abstract:* Value in Health. 2010 May; 13(3):A159. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)  
*Authors:* Chang JR, Yang W, Kahler KH, Fellers TS, Orloff J, Bensimon AG, Yu AP, Fan CPS, Wu EQ

**Economic impact of switching from valsartan to other angiotensin II receptor blockers (ARBs) in patients with hypertension**

*Abstract:* Value in Health. 2010 May; 13(3):A161. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)  
*Authors:* Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani H, Kahler KH

## DERMATOLOGY

**The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis**

*Publication:* JAAD 2011 in press  
*Authors:* Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, and Mulani PM

**Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial**

*Publication:* Am J Clin Dermatol. 2011 Feb 1;12(1):51-62  
*Authors:* Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM

**Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials**

*Publication:* Clin Drug Investig. 2011; 31(1):51-60  
*Authors:* Papp KA, Signorovitch J, Ramakrishnan K, Yu AP, Gupta SR, Bao Y, Mulani PM

**Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial**

*Publication:* J Am Acad Dermatol. 2010 Dec; 63(6):1011-8. Epub 2010 Oct 8.  
*Authors:* Reich K, Signorovitch J, Ramakrishnan K, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM

**Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept**

*Publication:* Pharmacoeconomics. 2010 Oct 1; 28(10):935-45.  
*Authors:* Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, Gupta SR, Mulani PM

**Economic burden of comorbidities in patients with psoriasis is substantial**

*Publication:* J Eur Acad Dermatol Venereol. 2011 Feb; 25(2):157-63. Epub 2010 Jun 17.  
*Authors:* Kimball AB, Guérin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM

**The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial**

*Publication:* J Am Acad Dermatol. 2010 May; 62(5):812-8. Epub 2010 Mar 9  
*Authors:* Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P

**Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis**

*Publication:* Am J Med. 2010 Apr; 123(4):350-7.  
*Authors:* Kimball AB, Guerin A, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P

**High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice**

*Publication:* Dermatology. 2010; 220(2):128-37. Epub 2010 Feb 3.  
*Authors:* Saurat JH, Guérin A, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, Bao Y, Mulani PM

**Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials**

*Publication:* Dermatology. 2010; 220(1):1-7. Epub 2009 Nov 19.  
*Authors:* Mease PJ, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM

**Economic burden of psoriasis compared to the general population and stratified by disease severity**

*Publication:* Curr Med Res Opin. 2009 Oct; 25(10):2429-38.  
*Authors:* Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, Mulani PM

**The impact of psoriasis on health care costs and patient work loss**

*Publication:* J Am Acad Dermatol 2008 Nov; 59(5): 772-80  
*Authors:* Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G

**The direct and indirect cost burden of atopic dermatitis: an employer-payer perspective**

*Publication:* Manag Care Interface. 2007 Oct; 20(10):26-32.  
*Authors:* Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G

**A survey-based assessment of the prevalence and severity of chronic hand dermatitis in a managed care organization**

*Publication:* Cutis. 2006 Jun; 77(6):385-92.

*Authors:* Fowler JF, Duh MS, Chang J, Person J, Thorn D, Raut M, Ghosh A, Den E, Reynolds J

**Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs**

*Publication:* J Am Acad Dermatol. 2006 Mar; 54(3):448-57.

*Authors:* Fowler JF, Ghosh A, Sung J, Emani S, Chang J, Den E, Thorn D, Person J, Duh MS

**Fatigue outcomes following withdrawal from and retreatment with adalimumab among patients maintained on adalimumab for moderate to severe psoriasis**

*Abstract:* Academy of Dermatology (AAD) 69th Annual Meeting, New Orleans, Louisiana, 4-8 February, 2011 (Poster)

*Authors:* Papp K, Wu EQ, Goldblum OM, Gupta SR

**Resource utilization and costs associated with switching from etanercept to adalimumab versus dose escalating with etanercept in patients with psoriasis**

*Abstract:* Academy of Dermatology (AAD) 69th Annual Meeting, New Orleans, Louisiana, 4-8 February, 2011 (Poster)

*Authors:* Wu EQ, Guérin A, Lyon-Caen S, Latremouille-Viau D, Yu AP, Gupta SR, Bao Y

**Health care outcomes associated with continuous use of adalimumab versus continuous and intermittent use of etanercept in patients with psoriasis**

*Abstract:* Academy of Dermatology (AAD) 69th Annual Meeting, New Orleans, Louisiana, 4-8 February, 2011 (Poster)

*Authors:* Wu EQ, Latremouille-Viau D, Guérin A, Cloutier M, Yu AP, Gupta SR, Bao Y

**ABT-874 versus etanercept or placebo treatment for moderate to severe psoriasis: health-related quality of life**

*Abstract:* Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, 6-10 October, 2010 (Poster)

*Authors:* Menter A, Signorovitch J, Parikh K, Yu AP, Wu EQ, Yoo S, Gu Y, Valdes J, Sundaram M, Bao Y, Mulani PM

**Longer disease duration of psoriasis with hand / foot involvement is independently associated with persistent impairment of work productivity and activity**

*Abstract:* 19th Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, 6-10 October, 2010 (Poster)

*Authors:* Kimball AB, Signorovitch J, Farooqui S, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM

**Adalimumab provides health-related quality-of-life benefits for patients with psoriasis with suboptimal response to etanercept methotrexate, or phototherapy**

*Abstract:* 19th Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, 6-10 October, 2010 (Poster)

*Authors:* Menter A, Guérin A, Yang H, Wu EQ, Yu AP, Gupta SR, Goldblum O, Bao Y, Mulani PM

**Resource utilization and costs in patients with moderate to severe psoriasis treated with adalimumab or etanercept in a real-world setting**

*Abstract:* 19th Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, 6-10 October, 2010 (Poster)

*Authors:* Wu EQ, Guérin A, Latremouille-Viau D, Yu AP, Cloutier M, Gupta SR, Bao Y, Mulani PM

**Effects of ABT-874 versus etanercept or placebo on health-related quality of life in patients with moderate to severe psoriasis**

*Abstract:* 19th Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, 6-10 October, 2010 (Poster)

*Authors:* Crowley J, Signorovitch J, Tsaneva M, Ramakrishnan K, Yu AP, Yoo S, Valdes J, Sundaram M, Bao Y, Mulani P

**Benefit-risk analysis of adalimumab for patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy**

*Abstract:* 19th Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, 6-10 October, 2010 (Poster)

*Authors:* Papp K, Guérin A, Parikh K, Signorovitch J, Yu AP, Wu EQ, Okun M, Gupta SR, Bao Y, Mulani PM

**Psoriasis treatment with ABT-874: effects on health-related quality of life and work productivity and activity impairment**

*Abstract:* 19th Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, 6-10 October, 2010 (Poster)

*Authors:* Papp K, Signorovitch J, Yang H, Yu AP, Wu EQ, Yoo S, Gu Y, Williams D, Valdes J, Sundaram M, Bao Y, Mulani P

**Adalimumab improves sleep symptoms in patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy**

*Abstract:* 19th Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, 6-10 October, 2010 (Poster)

*Authors:* Duffin KC, Guérin A, Yang H, Wu EQ, Yu AP, Gupta SR, Goldblum O, Bao Y, Mulani PM

**Cost per responder for biologic treatment of psoriasis: matching-adjusted comparisons of adalimumab with etanercept, infliximab, and ustekinumab**

*Abstract:* Journal of the American Academy of Dermatology, Mar 2010; 62(3 supp):AB3. American Academy of Dermatology (AAD) 68th Annual Meeting, Miami Beach, Florida, 5-9 March, 2010 (Poster)

*Authors:* Signorovitch J, Mulani P, Gupta S, Bao Y

**Cost-effectiveness of continuous adalimumab vs. continuous or intermittent etanercept for the treatment of psoriasis**

*Abstract:* American Academy of Dermatology (AAD) 68th Annual Meeting, Miami Beach, Florida, 5-9 March, 2010

*Authors:* Signorovitch J, Gupta SR, Bao Y, Mulani PM

**Comparative effectiveness of adalimumab versus ustekinumab treatment for psoriasis: clinical efficacy, safety and cost per responder**

*Abstract:* Journal of the American Academy of Dermatology, Mar 2010; 62(3 supp):AB125. American Academy of Dermatology (AAD) 68th Annual Meeting, Miami Beach, Florida, 5-9 March, 2010 (Poster)

*Authors:* Wu EQ, Signorovitch JE, Bao Y, Mulani PM

**Adalimumab monotherapy versus adalimumab plus betamethasone / calcipotriol combination therapy: effects on patient-reported outcomes in patients with psoriasis**

*Abstract:* American Academy of Dermatology (AAD) 68th Annual Meeting, Miami Beach, Florida, 5-9 March, 2010 (Poster)

*Authors:* Thaji D, Xie J, Gupta SR, Mulani PM

**Adalimumab versus ustekinumab treatment for psoriasis: clinical efficacy, safety and cost per responder**

*Abstract:* American Academy of Dermatology (AAD) 68th Annual Meeting, Miami Beach, Florida, 5-9 March, 2010 (Poster)

*Authors:* Wu EQ, Signorovitch JE, Bao Y, Mulani PM

## DIABETES

**Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes: a matching-adjusted indirect comparison of randomized trials**

*Publication:* Clin Drug Investig. 2011

*Authors:* Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger J-B

**Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus**

*Publication:* Curr Med Res Opin. 2011 Jan; 27(1):189-95. Epub 9 Dec, 2010

*Authors:* Pandya BJ, Bron M, McCall T, Yu AP, Chen KS, Mattson ME, Wu EQ

**Estimating the effect of medication adherence on health outcomes among patients with type 2 diabetes—an application of marginal structural models**

*Publication:* Value Health. 2010 Dec;13(8):1038-45.

Epub 12 Oct, 2010

*Authors:* Yu AP, Yu YF, Nichol MB

**Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis**

*Publication:* Diabetes Res Clin Pract. 2010 Jan; 87(1):108-16.

*Authors:* Lee LJ, Yu AP, Johnson SJ, Birnbaum HG, Atanasov P, Buesching DP, Jackson JA, Davidson JA

**Direct and indirect costs among employees with diabetic retinopathy in the United States**

*Publication:* Curr Med Res Opin. 2008 May; 24(5):1549-59. Epub 2008 Apr 15.

*Authors:* Lee LJ, Yu AP, Cahill KE, Oglesby AK, Tang J, Qiu Y, Birnbaum HG

**Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data**

*Publication:* Curr Med Res Opin. 2007 Sep; 23(9):2157-69.

*Authors:* Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A

**Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France**

*Publication:* Curr Med Res Opin. 2007 Sep; 23(9):2035-42.

*Authors:* Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S

**Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain**

*Publication:* J Pain. 2006 Jun; 7(6):399-407.

*Authors:* Wu EQ, Birnbaum HG, Mareva MN, Le TK, Robinson RL, Rosen A, Gelwicks S

**Productivity and medical costs of diabetes in a large employer population**

*Publication:* Diabetes Care. 2002 Jan; 25(1):23-9.

*Authors:* Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg PE

**Identification of diabetes patients using claims data: an economic analysis**

*Publication:* Drug Benefit Trends. 2001 Nov; 13(suppl B): 28-33.

*Authors:* Summers KH, Leong SA, Birnbaum HG, Greenberg PE, Kemner JE, Ramsey S

**Direct healthcare and indirect workloss costs associated with the addition of rosiglitazone (RSG) versus sitagliptin (STG) therapy to metformin (MET)**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Lefebvre P, Sarda SP, Laliberté F, Ramamurthy P, Wei R, Arondekar B, Menditto L, Martin AA, Duh MS

**Total and diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs from a large U.S. managed care cohort**

*Abstract:* Value in Health. 2010 Nov; 13(7):A526-7.

ISPOR 4th Asia-Pacific Conference, Phuket, Thailand, 5-7 September, 2010 (Poster)

*Authors:* Bron M, Yu A, Marynchenko M, Sun SX, Yang H, Wu EQ

**Economic effect of the clinical impact of bariatric surgery on morbidly obese patients with diabetes**

*Abstract:* American Society for Healthcare Engineering (ASHE) 47th Annual Conference, Tampa, Florida, 11-14 July, 2010 (Presentation)

*Authors:* Ghosh A, Crémieux PY, Klein S, Eapen S, McGavock T

**Relationship of hypoglycemia with medication, discontinuation and costs in type 2 diabetes mellitus patients**

*Abstract:* American Diabetes Association, 70th Scientific Sessions, Orlando, Florida, 25-29 June, 2010 (Poster)

*Authors:* Bron M, Yu AP, Marynchenko M, Yang H, Sun SX, Dabbous O

**Diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs**

*Abstract:* Journal of Managed Care Pharmacy. 2010 Mar; 16(2):147. Academy of Managed Care Pharmacy (AMCP) 22nd Annual Meeting & Showcase, San Diego, California, 7-10 April, 2010 (Poster)

*Authors:* Bron M, Yu AP, Marynchenko M, Sun SX, Yang H, Wu EQ

## ENDOCRINOLOGY

**Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients**

*Publication:* Value Health. 2007 Sep-Oct; 10(5):408-14.

*Authors:* Wu EQ, Mulani P, Farrell MH, Sleep D

**The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid**

*Publication:* Cancer. 2007 Mar; 109(6):1090-6.

*Authors:* Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antràs L, Smith M, Neary MP, Duh MS

## GASTROINTESTINAL DISORDERS

### **The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy**

*Publication:* Aliment Pharmacol Ther. 2010 Nov; 32(10):1228-39

*Authors:* Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD

### **Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease**

*Publication:* Inflamm Bowel Dis. 2010 Jun 1.

*Authors:* Loftus EV Jr, Johnson SJ, Wang ST, Wu E, Mulani PM, Chao J

### **Systematic review: the costs of ulcerative colitis in Western countries**

*Publication:* Aliment Pharmacol Ther. 2010 Apr;31(7):693-707

*Authors:* Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J

### **Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease**

*Publication:* Pharmacoeconomics. 2009; 27(7):609-21.

*Authors:* Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, Wu E, Chao J, Mulani PM

### **Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease**

*Publication:* Eur J Gastroenterol Hepatol. 2009 Nov; 21(11):1302-9.

*Authors:* Loftus EV Jr, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM

### **Impact of compliance with proton pump inhibitors on NSAID treatment**

*Publication:* Am J Manag Care. 2009 Oct; 15(10):681-8.

*Authors:* Duh MS, Gosselin A, Luo R, Lohoues H, Lewis BE, Crawley JA

### **Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial**

*Publication:* Am J Gastroenterol. 2009 May; 104(5):1170-9.

*Authors:* Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM

### **The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease**

*Publication:* Value Health. 2009 Jan-Feb; 12(1):34-9.

Epub 2008 Jul 15.

*Authors:* Gosselin A, Luo R, Lohoues H, Toy E, Lewis B, Crawley J, Duh MS

### **Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial**

*Publication:* Am J Gastroenterol. 2008 Oct 3.

*Authors:* Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani PM

### **Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study**

*Publication:* Gastroenterology. 2008 Aug 3.

*Authors:* Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV Jr, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani PM

### **Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective**

*Publication:* Value Health. 2008 May 16.

*Authors:* Wu EQ, Mulani PM, Yu AP, Tang J, Pollack PF

### **The costs of Crohn's disease in the United States and other Western countries: a systematic review**

*Publication:* Curr Med Res Opin. 2008 Feb; 24(2):319-28.

*Authors:* Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J

### **Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation**

*Publication:* Pharmacoepidemiol Drug Saf. 2006 Jan; 15(1):47-56.

*Authors:* Sands BE, Duh MS, Cali C, Ajene A, Bohn RL, Miller D, Cole JA, Cook SF, Walker AM

**Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors**

*Publication:* Dig Dis Sci. 2006 May; 51(5):877-84.  
*Authors:* Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH

**Computerized algorithms for the identification of irritable bowel syndrome, colonic ischemia, and complications of constipation: validation through medical records**

*Publication:* Pharmacoepidemiology and Drug Safety 2005 May 24  
*Authors:* Sands BE, Duh MS, Ajene A, Walker AM

**The economic consequences of irritable bowel syndrome: a U.S. employer perspective**

*Publication:* Arch Intern Med. 2003 Apr 28; 163(8):929-35.  
*Authors:* Leong SA, Barghout V, Birnbaum HG, Thibeault CE, Ben-Hamadi R, Frech F, Ofman JJ

**The economic and quality of life burden of illness in chronic constipation (CC) and irritable bowel syndrome (IBS): a systematic review**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)  
*Authors:* Yee K, Nellesen D, Chawla A, Carson R, Lewis B

**Use of inhaled tobramycin is associated with reduced mortality in patients with cystic fibrosis**

*Abstract:* 24th North American Cystic Fibrosis Conference, Baltimore, Maryland, October 21-23, 2010 (Poster)  
*Authors:* Sawicki GS, Signorovitch J, Latremouille-Viau D, von Wartburg M, Wu EQ, Zhang J, Shi L

**Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS)**

*Abstract:* American College of Gastroenterology Annual Scientific Meeting, San Antonio, Texas, 15-20 October, 2010 (Poster)  
*Authors:* Sussman D, Kubiliun N, Chao J, Mulani P, Gillis C, Yang M, Lu M, Abreu M

**Racial differences in use of biologics for Crohn's disease in a Medicaid population**

*Abstract:* American College of Gastroenterology Annual Scientific Meeting, San Antonio, Texas, 15-20 October, 2010 (Poster)  
*Authors:* Flasar M, Mulani P, Yang M, Chao J, Lu M, Cross R

**HEALTH ECONOMICS, POLICY, AND REGULATION**

**Economic outcomes of switching to another generic SSRI, escitalopram, or an SNRI among MDD patients treated with generic SSRI therapy**

*Publication:* American Journal of Pharmacy Benefits  
*Authors:* Marynchenko M, Yu AP, Lauzon V, Ramakrishnan K, Wu EQ, Ben-Hamadi R, Blum S, Erder MH, Bose A

**Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy**

*Publication:* Am J Ther. 2011 Feb 10.  
*Authors:* Wu EQ, Forsythe A, Guérin A, Yu AP, Latremouille-Viau D, Tsaneva M

**Care and costs: the sustained cost impact of reduced hospitalizations in a partnership-measurement model of disease management**

*Publication:* Healthcare Quarterly. 2010; 13(4).  
*Authors:* Paradis PE, Nemis-White J, Meilleur MC, Ginn M, Cox J, Montague T

**Introducing perspectives on comparative effectiveness research**

*Publication:* Pharmacoeconomics. 2010 Oct 1; 28(10):787-8.  
*Authors:* Birnbaum HG, Greenberg PE

**Perspectives on comparative effectiveness research: views from diverse constituencies**

*Publication:* Pharmacoeconomics. 2010 Oct 1; 28(10):789-98.  
*Authors:* Nellesen D, Birnbaum HG, Greenberg PE

**Methodological issues in a meta-analysis**

*Publication:* Hepatology. 2010 Jul; 52 (1): 395-6; author reply 396-7.  
Author: Crémieux PY

**A study on the economic impact of bariatric surgery**

*Publication:* Am J Manag Care. 2008 Sept; 14(9):589-96.  
*Authors:* Crémieux PY, Buchwald H, Shikora SA, Ghosh A, Yang E, Buessing M

**Retrospective economic and outcomes analyses using non-U.S. databases: a review**

*Publication:* Pharmacoeconomics. 2007; 25(7):563-76.  
*Authors:* Shi L, Wu EQ, Hodges M, Yu AP, Birnbaum HG

**Do drugs reduce utilization of other healthcare resources?**

*Publication:* Pharmacoeconomics. 2007; 25(3):209-21.  
*Authors:* Crémieux PY, Ouellette P, Petit P

**The role of epidemiology in drug safety litigations**

*Publication:* Update. 2007 Nov/Dec: 31-34  
*Authors:* Duh MS, Greenberg PE, Weiner JR

**Authorized generic drugs, price competition, and consumers' welfare**

*Publication:* Health Aff. 2007 May-Jun; 26(3):790-9.  
*Authors:* Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E

**The market for follow-on biologics: how will it evolve?**

*Publication:* Health Aff. 2006 Sep-Oct; 25(5):1291-1301.  
*Authors:* Grabowski H, Cockburn I, Long G

**A regulatory perspective on productivity claims: implications for future productivity research**

*Publication:* Health and Work Productivity: Emerging Issues in Research and Policy. R Kessler, P Stang (Eds.), Chicago, IL: University of Chicago Press, Spring 2006.  
*Authors:* Greenberg PE, Birnbaum HG

**Linking administrative claims data with archival productivity measures to inform employer decision making**

*Publication:* Health and Work Productivity: Emerging Issues in Research and Policy. R Kessler, P Stang (Eds.), Chicago, IL: University of Chicago Press, Spring 2006.  
*Authors:* Greenberg PE, Birnbaum HG

**Public and private pharmaceutical spending as determinants of health outcomes in Canada**

*Publication:* Health Econ. 2005 Feb; 14(2):107-16.  
*Erratum in:* Health Econ. 2005 Feb;14(2):117.  
*Authors:* Crémieux PY, Meilleur MC, Ouellette P, Petit P, Zelder M, Potvin K

**Your patent is about to expire: what now?**

*Publication:* Pharmaceutical Executive. 2004 Nov 1.  
*Authors:* Parece A, Tuttle E, Hector A

**Product liability in the pharmaceutical industry**

*Publication:* Update. 2004 Mar-Apr.  
*Authors:* Crémieux PY, Greenberg PE

**The relationship between technology availability and health care spending**

*Publication:* Health Aff. 2003 Jul-Dec; Suppl Web Exclusives: W3-537-51.  
*Authors:* Baker L, Birnbaum HG, Geppert J, Mishol D, Moyneur E

**Switching costs, price sensitivity and health plan choice**

*Publication:* J Health Econ. 2002 Jan; 21(1):89-116.  
*Authors:* Strombom BA, Buchmueller TC, Feldstein PJ

**L'évaluation de l'efficience budgétaire des CLSC au Québec à partir de la méthode DEA (An Evaluation of the budgetary efficiency of local community clinics in Quebec based on a DEA approach)**

*Publication:* L'Actualité Economique. 2001; 77(3):409-24.  
*Authors:* Crémieux PY, Gadbois D, Jaumard B, Ouellette P, Vovor T

**Pharmaceutical Spending and Health Outcomes in the United States?**

*Publication:* Investing in Health: The Social and Economic Benefits of HealthCare Innovation. K Summers, I Farquhar (Eds.), Elsevier Science Ltd., 2001.  
*Authors:* Greenberg PE, Crémieux PY, Ouellette P, Meilleur MC, Leong SA

**The effects of chronic medical conditions on work loss and work cutback**

*Publication:* J Occup Environ Med. 2001 Mar; 43(3):218-25.  
*Authors:* Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS

**Actual and perceived impacts of tobacco regulation on restaurants and firms**

*Publication:* Tob Control. 2001 Mar; 10(1):33-7.  
*Authors:* Crémieux PY, Ouellette P

**Impact of illness and its treatment on workplace costs: regulatory and measurement issues**

*Publication:* J Occup Environ Med. 2001 Jan; 43(1):56-63.

*Authors:* Greenberg PE, Birnbaum HG, Kessler RC, Morgan M, Stang P

**Diagnosing the illness**

*Publication:* Policy Options. 2000; 12(4):12-4.

*Authors:* Crémieux PY, Ouellette P

**Health care spending as determinants of health outcomes**

*Publication:* Health Econ. 1999 Nov; 8(7):627-39.

*Authors:* Crémieux PY, Ouellette P, Pilon C

**Pharmacoeconomics and health policy. Current applications and prospects for the future**

*Publication:* Pharmacoeconomics. 1999 Nov; 16(5 Pt 1):425-32.

*Authors:* Greenberg PE, Arcelus A, Birnbaum HG, Crémieux PY, LeLorier J, Ouellette P, Slavin MB

**Using healthcare claims data for outcomes research and pharmacoeconomic analyses**

*Publication:* Pharmacoeconomics. 1999 Jul; 16(1):1-8.

*Authors:* Birnbaum HG, Crémieux PY, Greenberg PE, LeLorier J, Ostrander JA, Venditti L

**Tackling costs one disease at a time**

*Publication:* Bus Health. 1999 May; 17(5):31-2.

*Author:* Greenberg PE

**Calculating return on investment from reducing workplace costs of illness**

*Publication:* Drug Benefit Trends. 1998 Mar.

*Authors:* Greenberg PE, Baker A, Berndt E, Finkelstein S, Russell J

**Etude d'impact du projet de loi sur le tabac (Impact report on the proposed tobacco law)**

*Publication:* Ministry of Health and Social Services. 1997.

*Authors:* Crémieux PY, Fortin P, Lavoie F, Ouellette P, St Pierre Y

**The next phase of managed care: targeting investments in employee health**

*Publication:* On Managed Care. 1997 Sept.

*Authors:* Greenberg PE, Berndt E, Finkelstein S

**Une analyse du contexte budgétaire de l'activité médicale au Québec (An analysis of the budgetary context of medical activity in Québec)**

*Publication:* Le Médecin du Québec. 1997 Aug.

*Authors:* Crémieux PY, Ouellette P

**Economic consequences of illness in the workplace**

*Publication:* Sloan Management Review. 1995 Summer.

*Authors:* Greenberg P, Finkelstein S, Berndt E

**Consolidation and restructuring: the next step in managed care**

*Publication:* Health Care Manag. 1995 Oct; 2(1):221-35.

*Authors:* Danzon PM, Boothman LG, Greenberg PE

**Calculating the workplace cost of chronic disease**

*Publication:* Bus Health. 1995 Sep; 13(9):27-8.

*Authors:* Greenberg PE, Finkelstein SN, Berndt ER

**When can a Medicare insured group (MIG) succeed?**

*Publication:* Inquiry. 1994.

*Authors:* Birnbaum HG, Causino N, Lang K

**Savings estimate for a Medicare insured group**

*Publication:* Health Care Finance Rev. 1991 Summer; 12(4):39-48.

*Authors:* Birnbaum HG, Holland SK, Lenhart G, Reilly HL, Hoffman K, Pardo DP

**Panel discussion: new imperatives for evidence to support successful licensing, reimbursement, and commercial strategy**

*Conference:* BIO International Convention, Chicago, IL, 6 May, 2010

*Panelists:* Chawla A (moderator), Szela M, Blansett L, Garrison L, Schroeder T

**Healthcare resource utilization and costs in females with newly diagnosed heavy menstrual bleeding: an employer's perspective**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Jensen JF, Lefebvre P, Laliberté F, Sarda SP, Law A, Pocoski J, Duh MS

**Direct and indirect costs of privately-insured patients treated with oxymorphone extended-release or oxycodone controlled-release tablets**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Kirson NY, White AG, Birnbaum HG, Schiller M, Waldman T, Ben-Joseph RH, Berner T, Summers KH

### **Racial differences in use of biologics for Crohn's disease in a Medicaid population**

*Abstract:* American College of Gastroenterology Annual Scientific Meeting, San Antonio, Texas, 15-20 October, 2010 (Poster)

*Authors:* Flasar M, Mulani P, Yang M, Chao J, Lu M, Cross R

### **The direct and indirect costs associated with hypogonadism among U.S. privately-insured employees**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Podium)

*Authors:* Kaltenboeck A, Foster S, Thomas N, Ivanova J, Diener M, Bergman R, Birnbaum H, Swindle R

### **Improved indirect treatment comparisons for comparative effectiveness research**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Workshop)

*Authors:* Signorovitch J, Navarro R, Betts K, Wu EQ

## **HEMATOLOGY**

### **Red blood cell transfusions and the risk of ARDS among critically ill: a cohort study**

*Publication:* Crit Care 2007 Jun 6; 11 (3): R63

*Authors:* Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, Shorr AF

### **Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease (SCD)**

*Abstract:* Value in Health. 2010 May; 13(3):A212. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS

### **Comparison of healthcare resource utilization and costs between nilotinib and dasatinib as second line therapies in chronic myeloid leukemia (CML)**

*Abstract:* Value in Health. 2010 May; 13(3):A32. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Wu EQ, Bollu V, Guo A, Guérin A, Tsaneva M, Williams D, Griffin JD

### **Non-adherence to imatinib in chronic myeloid leukemia (CML) patients is associated with short- and long-term negative impacts on healthcare resource utilization and costs**

*Abstract:* Value in Health. 2010 May; 13(3):A32. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Guérin A, Bollu V, Guo A, Wu EQ, Yu AP, Sirulnik LA, Griffin JD

### **Costs to Medicare of treating chronic lymphocytic leukemia patients with alemtuzumab**

*Abstract:* Value in Health. 2010 May; 13(3):A32. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Lafeuille MH, Vekeman F, Kerrigan M, Wang ST, Duh MS

### **Lower health care resource utilization associated with managing nilotinib related adverse events in chronic myeloid leukemia (CML) patients: evidence from a clinical practice setting study**

*Abstract:* Value in Health. 2010 May; 13(3):A33. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Guérin A, Bollu V, Williams D

### **Modeling the cost-effectiveness of bortezomib for the initial treatment of multiple myeloma in the United States**

*Abstract:* Value in Health. 2010 May; 13(3):A210. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Wang ST, Huang H, Shi H, Duh MS, Chen K, Chang E, Korves C, Dhawan R, Cakana A, van de Velde H, Esseltine DL, Garrison L

## **HOSPITALS**

### **Hospital cost flexibility in the presence of many outputs: a public-private comparison**

*Publication:* Health Care Manag Sci. 2005 May; 8(2):111-20.

*Authors:* Crémieux PY, Ouellette P, Rimbaud F, Vigeant S

### **Measuring hospital efficiency in the presence of quasi-fixed inputs: an analysis of Québec hospitals**

*Publication:* Journal of Productivity Analysis. 2004; 21(2):183-99.

*Authors:* Bilodeau D, Crémieux PY, Jaumard B, Ouellette P, Vovor T

### **Hospital technology in a non-market health care system**

*Publication:* Southern Economic Journal. 2002; 68(3):511-29.

*Authors:* Bilodeau D, Crémieux PY, Ouellette P

### **Omitted variable bias and hospital costs**

*Publication:* J Health Econ. 2001 Mar; 20(2):271-82.

*Authors:* Crémieux PY, Ouellette P

### **Hospital cost function in a non-market health care system**

*Publication:* Review of Economics and Statistics. 2000; 82(3):1-11.

*Authors:* Bilodeau D, Crémieux PY, Ouellette P

### **La performance des CLSC au Québec, (Local health clinic performance in Quebec)**

*Publication:* L'Actualité Economique. 1998; 74(2):157-81.

*Authors:* Crémieux PY, Ouellette P, Gadbois D

## **LONG-TERM CARE**

### **The home infusion therapy/relative benefit index: summary of an analysis using insurance claims data**

*Publication:* Med Care. 1998 May; 36(5):757-65.

*Authors:* Birnbaum HG, Tang M

### **An alternative in terminal care: results of the National Hospice Study**

*Publication:* J Chronic Dis. 1986; 39(1):9-26.

*Authors:* Greer DS, Mor V, Morris JN, Sherwood S, Kidder D, Birnbaum HG

### **Impacts of the New York long-term home health care program**

*Publication:* Medical Care. 1986; 24(7).

*Authors:* Birnbaum HG, Gaumer G, Pratter F, Burke R, Franklin S, Ellington-Otto K

### **What does hospice cost?**

*Publication:* Am J Public Health. 1984 Jul; 74(7):689-97.

*Authors:* Birnbaum HG, Kidder D

### **Implementing community-based long-term care: experience of the long-term home health care program**

*Publication:* The Gerontologist. 1984 Summer; 24(4).

*Authors:* Birnbaum HG, Burke R, Swearingen C, Dunlop B

### **How does the nursing home sector behave: a multi-equation model of nursing home behavior**

*Publication:* Social Science and Medicine. 1983; 17(23):1897-1906.

*Authors:* Birnbaum HG, Lee AJ, Bishop C

### **National hospice study analysis plan**

*Publication:* J Chronic Dis. 1983; 36(11):737-80.

*Authors:* Greer DS, Mor V, Sherwood S, Morris JN, Birnbaum HG

### **Managing programs for the elderly: design of a social information systems**

*Publication:* Health Care Finance Rev. 1983 Winter; 5(2):11-23.

*Authors:* Birnbaum HG, Burke R, Pratter F

### **Home care in hospices**

*Publication:* Caring. 1983 Jun; 2(6):40-4.

*Authors:* Birnbaum HG, Mor V, Greer DS

### **The determinants of nursing home operating costs in New York State**

*Publication:* Health Serv Res. 1983 Summer; 18(2 Pt 2):285-308.

*Authors:* Lee AJ, Birnbaum HG

### **Medicare legislation for hospice care: implications of national hospice study data**

*Publication:* Health Aff. 1983 Summer; 2(2):80-90.

*Authors:* Mor V, Birnbaum HG

### **Why do nursing home costs vary? The determinants of nursing home costs**

*Publication:* Med Care. 1981 Nov; 19(11):1095-107.

*Authors:* Birnbaum HG, Bishop C, Lee AJ, Jensen G

## **MEDICATION COMPLIANCE**

### **Persistence and adherence in patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs. single long-acting inhalers**

*Abstract:* Chest. 2010 Oct; 138(4):482A. American College of Chest Physicians CHEST 2010 Meeting,

Vancouver, B.C., Canada, 30 October-4 November, 2010 (Poster)

*Authors:* Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI

**Persistence with nebivolol compared to other  $\beta$ -blockers in the treatment of hypertension: a retrospective claims analysis**

*Abstract:* American Heart Association, High Blood Pressure Research Conference 2010 Scientific Sessions, Washington, D.C., 13-16 October, 2010 (Poster)

*Authors:* Signorovitch J, Samuelson T, Ramakrishnan K, Marynchenko M, Blum SI, Ramasamy A, Wu EQ

**Compliance and health care utilization among patients with hypertension treated with single pill vs. free combination antihypertensive therapy: U.S. national and state level results from a claims database analysis**

*Abstract:* Value in Health. 2010 May; 13(3):A159. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Yang W, Chang JR, Kahler KH, Fellers TS, Orloff J, Wu EQ, Bensimon AG, Fan CPS, Yu AP

**Relationship between daily dosing frequency, compliance, healthcare resource use, and costs: evidence from the treatment of chronic obstructive pulmonary disease (COPD)**

*Abstract:* Value in Health. 2010 May; 13(3):A201. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat C, Swensen A, Duh MS

**Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease (SCD)**

*Abstract:* Value in Health. 2010 May; 13(3):A212. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS

**The role of compliance in telehealth adoption**

*Abstract:* 15th Annual International Meeting of the American Telemedicine Association, San Antonio, Texas, 16-18 May, 2010 (Poster)

*Authors:* Newell D, Johnson S, Rutherford P, Welte I

## MENTAL HEALTH

**Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors**

*Publication:* Curr Med Res Opin. 2011 Mar 28.

*Author:* Signorovitch J, Ramakrishnan K, Ben-Hamadi R, Yu AP, Wu EQ, Dworak H, Haim Erder M

**Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic Selective serotonin reuptake inhibitor in patients with major depressive disorder**

*Publication:* Ann Pharmacother. 2011 Mar 17.

*Authors:* Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH

**Perceptions and prescribing considerations among U.S. psychiatrists regarding drug-drug interactions associated with oral atypical antipsychotics**

*Publication:* Curr Med Res Opin. 2010 Dec;26(12):2735-44

*Authors:* Frois C, Guérin A, Saraogi A, Panish J, Dirani R

**Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study**

*Publication:* J Med Econ. 2010;13:599-609

*Authors:* Yu AP, Xie J, Bensimon A, Parikh K, Wu EQ, Ben-Hamadi R, Blum S, Erder HM

**Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil**

*Publication:* Drugs Aging. 2010; 27(11):903-913.

*Authors:* Scharre DW, Vekeman F, Lefebvre P, Mody-Patel N, Kahlers KH, Duh MS

**Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States**

*Publication:* Journal of Occupational and Environmental Medicine. 2010; 52(2):115-124.

*Authors:* Birnbaum HG, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Kantor E, Crémieux PY, Greenberg PE

**Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons**

*Publication:* J Med Econ. 2010; 13(2):314-323.

*Authors:* Wu EQ, Ben-Hamadi R, Yu AP, Tang J, Haim Erder M, Bose A

**Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance**

*Publication:* Depress Anxiety. 2010; 27(1):78-89.

*Authors:* Birnbaum HG, Kessler RC, Kelley D, Ben-Hamadi R, Joish VN, Greenberg PE

**Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder**

*Publication:* Curr Med Res Opin. 2010 Oct; 26(10):2475-84.

*Authors:* Ivanova JI, Birnbaum HG, Kidolezi Y, Subramanian G, Khan SA, Stensland MD

**Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%**

*Publication:* J Med Econ. 2010 Sep; 13(3):472-81.

*Authors:* Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Amy Puenpatom R, Ben-Joseph RH, Summers KH

**Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin**

*Publication:* J Med Econ. 2010 Sep; 13(3):482-91.

*Authors:* Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Puenpatom RA, Ben-Joseph RH, Summers KH

**Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons**

*Publication:* J Med Econ. 2010 Jun; 13(2):314-23.

*Authors:* Wu EQ, Ben-Hamadi R, Yu AP, Tang J, Haim Erder M, Bose A

**The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial**

*Publication:* J Am Acad Dermatol. 2010 May; 62(5):812-8. Epub 2010 Mar 9.

*Authors:* Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P

**Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States**

*Publication:* J Occup Environ Med. 2010 Feb; 52(2):115-24.

*Authors:* Birnbaum HG, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Kantor E, Crémieux PY, Greenberg PE

**Determinants of direct cost differences among U.S. employees with major depressive disorders using antidepressants**

*Publication:* Pharmacoeconomics. 2009; 27:6.

*Authors:* Birnbaum HG, Ben-Hamadi R, Greenberg PE, Hsieh M, Tang J, Grobelle CR

**Age differences in the prevalence and comorbidity of DSM-IV major depressive episodes: results from the WHO World Mental Health Survey Initiative**

*Publication:* Depress Anxiety. 2009 Dec 27

*Authors:* Kessler RC, Birnbaum HG, Shahly V, Bromet E, Hwang I, McLaughlin KA, Sampson N, Andrade LH, de Girolamo G, Demyttenaere K, Haro JM, Karam AN, Kostyuchenko S, Kovess V, Lara C, Levinson D, Matschinger H, Nakane Y, Browne MO, Ormel J, Posada-Villa J, Sagar R, Stein DJ

**Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia**

*Publication:* J Pain. 2009 Sep; 10(9):976-83.

*Authors:* White LA, Robinson RL, Yu AP, Kaltenboeck A, Samuels S, Mallett D, Birnbaum HG

**Treatment persistence, healthcare utilization and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs**

*Publication:* J Med Econ. 2009 Jun; 12(2):124-35.

*Authors:* Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH

**Antidepressant treatment patterns and costs among U.S. employees**

*Publication:* J Med Econ. 2009 Mar; 12(1):36-45.

*Authors:* Birnbaum H, Greenberg PE, Tang J, Hsieh M, Wu EQ, Amand C, Ben-Hamadi R

**Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population**

*Publication:* Curr Med Res Opin. 2009 Mar; 25(3):755-64.

*Authors:* Yu AP, Ben-Hamadi R, Birnbaum HG, Atanasov P, Stensland MD, Philips G

**Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population**

*Publication:* Value Health. 2009 Jan 9.

*Authors:* Yu AP, Atanasov P, Ben-Hamadi R, Birnbaum H, Stensland MD, Philips G

**Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants**

*Publication:* Curr Med Res Opin. 2008; 24(10):2805-13.

*Authors:* Wu EQ, Greenberg PE, Yang E, Yu A, Ben-Hamadi R, Erder MH

**Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population**

*Publication:* Curr Med Res Opin. 2008; 24(9):2587-2595.

*Authors:* Wu EQ, Greenberg PE, Yang E, Yu AP, Erder MH

**Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies**

*Publication:* J Manag Care Pharm. 2007 Sep; 13(7):561-9.

*Authors:* Wu EQ, Birnbaum HG, Zhang HF

**Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication**

*Publication:* Arch Gen Psychiatry. 2007 May; 64(5):543-52.

*Authors:* Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC

**Considering the costs of bipolar depression**

*Publication:* Behav Healthc. 2007 Jan; 27(1):45-7.

*Authors:* Kessler RC, Akiskal HS, Ames M, Birnbaum HG, Greenberg PE, Hirschfeld RM, Wang PS

**Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach**

*Publication:* Psychol Med. 2006 Nov; 36(11):1535-40.

Epub 2006 Aug 15.

*Authors:* Wu EQ, Shi L, Birnbaum HG, Hudson T, Kessler RC

**Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers**

*Publication:* Am J Psychiatry. 2006 Sep; 163(9):1561-8.

*Authors:* Kessler RC, Akiskal HS, Ames M, Birnbaum HG, Greenberg PE, A RM, Jin R, Merikangas KR, Simon GE, Wang PS

**The economic burden of depression in the U.S.: societal and patient perspectives**

*Publication:* Expert Opin Pharmacother. 2005 Mar; 6(3):369-76.

*Authors:* Greenberg PE, Birnbaum HG

**The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R)**

*Publication:* Biol Psychiatry. 2005 Oct 15; 58(8):668-76.

*Authors:* Kessler RC, Birnbaum HG, Demler O, Falloon IR, Gagnon E, Guyer M, Howes MJ, Kendler KS, Shi L, Walters E, Wu EQ

**The economic burden of schizophrenia in the United States in 2002**

*Publication:* J Clin Psychiatry. 2005 Sep; 66(9):1122-9.

*Authors:* Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J

**The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers**

*Publication:* J Occup Environ Med. 2005 Jun; 47(6):565-72.

*Authors:* Kessler RC, Adler L, Ames M, Barkley RA, Birnbaum HG, Greenberg PE, Johnston JA, Spencer T, Ustun TB

**Costs of attention deficit-hyperactivity disorder (ADHD) in the U.S.: excess costs of persons with ADHD and their family members in 2000**

*Publication:* Curr Med Res Opin. 2005 Feb; 21(2):195-206.

*Authors:* Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA, Swensen AR

**Economic implications of treatment-resistant depression among employees**

*Publication:* Pharmacoeconomics. 2004; 22(6):363-73.  
*Authors:* Greenberg PE, Corey-Lisle PK, Birnbaum HG, Marynchenko M, Claxton A

**What's so different about anxiety disorders (such as phobias)?**

*Publication:* Phobias (vol. 7 of the World Psychiatric Association series "Evidence and Experience in Psychiatry"), John Wiley & Sons, Ltd. 2004; 337-339.  
*Authors:* Greenberg PE, Birnbaum HG, Sisitsky T

**Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients**

*Publication:* J Adolesc Health. 2004 Oct; 35(4):346-9.  
*Authors:* Swensen A, Birnbaum HG, Ben-Hamadi R, Greenberg PE, Crémieux PY, Secnik K

**Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently**

*Publication:* J Rheumatol. 2004 Aug; 31(8):1621-9.  
*Authors:* Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Wolfe F

**Money can't buy happiness...**

*Publication:* Business & Health. 2004 April 15.  
*Authors:* Greenberg PE, Birnbaum HG, Kessler RC

**The economic burden of depression with painful symptoms**

*Publication:* J Clin Psychiatry. 2003; 64 Suppl 7:17-23.  
*Authors:* Greenberg PE, Leong SA, Birnbaum HG, Robinson RL

**Economic impact of olanzapine plus fluoxetine combination therapy among patients treated for depression: a pilot study**

*Publication:* Psychopharmacology Bulletin. 2003 Summer; 37(3):90-8.  
*Authors:* Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Dube S

**The economic burden of depression in the United States: how did it change between 1990 and 2000?**

*Publication:* J Clin Psychiatry. 2003 Dec; 64(12):1465-75.  
*Authors:* Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK

**Attention-deficit/hyperactivity disorder: increased costs for patients and their families**

*Publication:* J Am Acad Child Adolesc Psychiatry. 2003 Dec; 42(12):1415-23.  
*Authors:* Swensen AR, Birnbaum HG, Secnik K, Marynchenko M, Greenberg PE, Claxton A

**Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis**

*Publication:* J Clin Psychiatry. 2003 Oct; 64(10):1201-9.  
*Authors:* Birnbaum HG, Shi L, Dial E, Oster EF, Greenberg PE, Mallett DA

**The economics of women and depression: an employer's perspective**

*Publication:* J Affect Disord. 2003 Mar; 74(1):15-22.  
*Authors:* Birnbaum HG, Leong SA, Greenberg PE

**The economic burden of anxiety and stress disorders**

*Publication:* Neuropsychopharmacology: The Fifth Generation of Progress. K Davis (Ed.), Baltimore, MD: The American College of Neuropsychopharmacology and Lippincott Williams & Wilkins 2002; 67:981-92  
*Authors:* Kessler RC, Greenberg PE

**Identification of a claims data "signature" and economic consequences for treatment-resistant depression**

*Publication:* J Clin Psychiatry. 2002 Aug; 63(8):717-26.  
*Authors:* Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ

**An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts**

*Publication:* J Ment Health Policy Econ. 2002 Mar; 5(1):3-19.  
*Authors:* Berndt ER, Bhattacharjya A, Mishol DN, Arcelus A, Lasky T

**Cost of depression: current assessment and future directions**

*Publication:* Expert Review of Pharmacoeconomics & Outcomes Research. 2001 Oct; 1(1):69-76.  
*Authors:* Greenberg PE, Leong S, Birnbaum HG

**Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD**

*Publication:* Neurology. 2001 Sep 25; 57(6):957-64.

*Authors:* Neumann PJ, Araki SS, Arcelus A, Longo A, Papadopoulos G, Kosik KS, Kuntz KM, Bhattacharjya A

**Assessing the economic impact of psychiatric disorders: where to begin?**

*Publication:* Expert Opin Pharmacother. 2001 Apr; 2(4):641-52.

*Authors:* Greenberg PE, Leong SA, Birnbaum HG

**Depression and work productivity: the comparative costs of treatment versus nontreatment**

*Publication:* J Occup Environ Med. 2001 Jan; 43(1):2-9.

*Authors:* Simon GE, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, Wang PS, Kessler RC

**The workplace burden of depression: underlying causes, recent empirical findings, and future directions**

*Publication:* TEN. 2000; 2(6):37-40.

*Authors:* Greenberg PE, Birnbaum HG

**Management of major depression in the workplace: impact on employee work loss**

*Publication:* Disease Management & Health Outcomes. 2000; 7(3):163-71.

*Authors:* Kessler R, Birnbaum HG, Crémieux PY, Greenberg PE

**The impact of antidepressant use on social functioning: reboxetine versus fluoxetine**

*Publication:* Int Clin Psychopharmacol. 2000 Sep; 15(5):279-89.

*Authors:* Venditti LN, Arcelus A, Birnbaum HG, Greenberg PE, Barr CE, Rowland C, Williamson T

**Workplace burden of depression: case study in social functioning using employer claims data**

*Publication:* Drug Benefit Trends. 1999; 11(8):6-12.

*Authors:* Birnbaum HG, Greenberg PE, Barton M, Kessler RC, Rowland C, Williamson T

**Depression in the workplace: effects on short-term disability**

*Publication:* Health Aff. 1999 Sep-Oct; 18(5):163-71.

*Authors:* Kessler RC, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, Simon GE, Wang P

**The economic burden of anxiety disorders in the 1990s**

*Publication:* J Clin Psychiatry. 1999 Jul; 60(7):427-35.

*Authors:* Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, Ballenger JC, Fyer AJ

**Workplace performance effects from chronic depression and its treatment**

*Publication:* J Health Econ. 1998 Oct; 17(5):511-35.

*Authors:* Berndt ER, Finkelstein SN, Greenberg PE, Howland RH, Keith A, Rush AJ, Russell J, Keller MB

**Improvement in subjective work performance after treatment of chronic depression: some preliminary results. Chronic Depression Study Group**

*Publication:* Psychopharmacol Bull. 1996; 32(1):33-40.

*Authors:* Finkelstein SN, Berndt ER, Greenberg PE, Parsley RA, Russell JM, Keller MB

**Depression in the workplace: an economic perspective**

*Publication:* Selective Serotonin Re-Uptake Inhibitors: Advances in Basic Research and Clinical Practice. JP Feighner, WF Boyer (Eds.), New York, John Wiley & Sons 1996:327-63.

*Authors:* Greenberg PE, Kessler RC, Nells TL, Finkelstein SN, Berndt ER

**Depression: a neglected major illness**

*Publication:* J Clin Psychiatry. 1993 Nov; 54(11):419-24.

*Authors:* Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER

**The economic burden of depression in 1990**

*Publication:* J Clin Psychiatry. 1993 Nov; 54(11):405-18.

*Authors:* Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER

**Comparison of real-world healthcare costs after the initiation of second-line duloxetine or generic selective serotonin reuptake inhibitors in patients with major depressive disorder**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Swindle R, Ivanova JI, Birnbaum HG, Cumming AK, Kantor E, Schiller M, Clark T, Reed C

**The cost-effectiveness of guanfacine extended release (GXR) versus atomoxetine (ATX) for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Erder MH, Xie J, Chen K, Wu E, Hodgkins P, Sikirica V

**Cost of illness of post-traumatic stress disorder compared with major depressive disorder**

*Abstract:* Value in Health. 2010 May; 13(3):A111. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Ivanova J, Birnbaum H, Chen L, Dayoub E, Kantor E, Phillips G

**MUSCULOSKELETAL DISEASE**

**The cost of disability and medically related absenteeism among employees with multiple sclerosis in the U.S.**

*Publication:* Pharmacoeconomics. 2009; 27(8):681-91.

*Authors:* Ivanova JI, Birnbaum HG, Samuels S, Davis M, Phillips AL, Meletiche D

**Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs**

*Publication:* Curr Med Res Opin. 2009 Apr; 25(4):869-77.

*Authors:* Birnbaum HG, Ivanova JI, Samuels S, Davis M, Crémieux PY, Phillips AL, Meletiche D

**Actual versus predicted first-year utilization patterns of teriparatide in patients with employer-sponsored health insurance**

*Publication:* Curr Med Res Opin. 2007 Dec; 23(12):3215-22.

*Authors:* Meadows ES, Rousculp M, Sasser AC, Birnbaum HG, Moyneur E, Mallet D, Johnston JA

**Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population**

*Publication:* Womens Health Issues. 2005 May-Jun; 15(3):97-108.

*Authors:* Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D

**The effectiveness of surgery on the treatment of acute spinal cord injury and its relation to pharmacological treatment**

*Publication:* Neurosurgery. 1994 Aug; 35(2):240-8; discussion 248-9.

*Authors:* Duh MS, Shepard MJ, Wilberger JE, Bracken MB

**Relationship between adherence to disease-modifying drugs and severe relapses, direct and indirect costs among employees with multiple sclerosis**

*Abstract:* 63rd Annual Meeting of the American Academy of Neurology, Honolulu, HI, April 9-16 2011 (Poster)

*Authors:* Philips AL, Ivanova JI, Bergman RE, Birnbaum HG, Stewart M, Meletiche DM

**Real-world use of duloxetine for low back pain and chronic low back pain: treatment patterns, direct and indirect costs**

*Abstract:* Value in Health. 2010 May; 13(3):A126. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Johnstone B, Faries D, Risser R, Swindle R

**NEPHROLOGY**

**Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review**

*Publication:* J Cancer Res Ther. 2010 Jan-Mar;6(1):31-5

*Authors:* Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS

**Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective**

*Publication:* J Manag Care Pharm. 2009 May; 15(4):312-22.

*Authors:* Laliberté F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P

**The economic impact of pre-dialysis epoetin alfa on health care and work loss costs in chronic kidney disease: an employer's perspective**

*Publication:* Dis Manag. 2008 Feb; 11(1):49-58.

*Authors:* Moyneur E, Bookhart BK, Mody SH, Fournier AA, Mallett D, Duh MS

**Medical and work loss burden of pre-dialysis chronic kidney disease and related anemia: an employer's perspective**

*Publication:* Journal of Health & Productivity 2007 (Oct): 3-9

*Authors:* Moyneur E, Bookhart BK, Mody SH, Fournier A, Mallet D, Duh MS

**Comment on: the relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease**

*Publication:* Curr Med Res Opin. 2007 Jul; 23(7):1571-4.  
*Authors:* Einarson T, Machado M, Walker J, Iskedjian M, Crémieux PY, Van Audenrode M, Lefebvre P

**The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease**

*Publication:* Dis Manag. 2007 Feb; 10(1):37-45.  
*Authors:* Lefebvre P, Duh MS, Mody SH, Bookhart B, Piech CT

**Interstitial cystitis: cost, treatment and comorbidities in an employed population**

*Publication:* Pharmacoeconomics. 2006; 24(1):55-65.  
*Authors:* Wu EQ, Birnbaum HG, Mareva M, Parece A, Huang Z, Mallett D, Taitel H

**Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organizations**

*Publication:* Drugs Aging. 2006; 23(12):969-76.  
*Authors:* Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT

**The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease**

*Publication:* Curr Med Res Opin. 2006 Dec; 22(12):2329-36.  
*Authors:* Crémieux PY, Van Audenrode M, Lefebvre P

**Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations**

*Publication:* Clin Ther. 2006 Sep; 28(9):1443-50.  
*Authors:* Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Piech CT

**A retrospective claims database analysis to assess patterns of interstitial cystitis diagnosis**

*Publication:* Curr Med Res Opin. 2006 March; 22(3):495-500.  
*Authors:* Wu EQ, Birnbaum HG, Kang YJ, Parece A, Mallett D, Taitel H, Evans RJ

**Assessing the risk of clinical fracture in men with non-metastatic prostate cancer receiving gonadotropin-releasing hormone agonist therapy**

*Publication:* J of Urology 2006 Jan; 175(1):136-9; discussion 139  
*Authors:* Smith MR, Boyce SP, Moyneur E, Duh MS, Raut M, Brandman J

**Employees with overactive bladder: work loss burden**

*Publication:* J Occup Environ Med. 2005 May; 47(5):439-46.  
*Authors:* Wu EQ, Birnbaum HG, Marynchenko M, Mareva M, Williamson T, Mallett D

**Cost of stress urinary incontinence: a claims data analysis**

*Publication:* Pharmacoeconomics. 2004; 22(2):95-105.  
*Authors:* Birnbaum HG, Leong SA, Oster EF, Kinchen K, Sun P

**Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis**

*Publication:* Pharmacotherapy. 2003 May; 23(5):690-3.  
*Authors:* Barnett AL, Crémieux PY

**Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts**

*Publication:* Pharmacoepidemiol Drug Saf. 1999 Jul; 8(4):275-83.  
*Authors:* Duh MS, Walker AM, Kronlund KH Jr

**Prediction and cross-validation in modeling incident cases of hepatic disorders using automated medical data**

*Publication:* American Journal of Epidemiology 1998; 147:407-13  
*Authors:* Duh MS, Walker AM, Pagano M, Kronlund K

**Dosing pattern and cost comparison of epoetin alfa and darbepoetin alfa in chronic kidney disease and chemotherapy-induced anemia inpatients**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)  
*Authors:* Lafeuille MH, Bailey RA, Senbetta M, McKenzie RS, Lefebvre P

**Patterns of angiogenesis inhibitor treatment in patients with metastatic renal cell carcinoma in Ireland**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)  
*Authors:* McDermott R, Donnellan P, McCaffrey J, Keane F, Sarda SP, Korves C, Luka A, Wei R, Neary MP, Hanley R, Duh MS

**Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma in United Kingdom**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)  
*Authors:* Hawkins R, Wagstaff J, Nathan P, Sarda SP, Vekeman F, Korves C, Dasgupta S, O'Mara S, Fitton S, Hayners J, Tham C, Wei R, Luka A, Neary MP, Duh MS

**Burden of uncontrolled epilepsy in a privately-insured population**

*Abstract:* 63rd Annual Meeting of the American Academy of Neurology, Honolulu, HI, April 9-16 2011 (Poster)  
*Authors:* Manjunath R, Faught E, Paradis PE, Parisé H, Lafeuille MH, Lefebvre P, Duh MS

**Erythropoiesis-stimulating agents utilization and costs in patients with chronic kidney disease not on dialysis from two large claims databases**

*Abstract:* Value in Health. 2010 May; 13(3):A77. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)  
*Authors:* Lafeuille MH, Bailey RA, Laliberté F, Senbetta M, Blacksmith A, Lefebvre P

**Seven year trends of pharmacy benefit erythropoiesis-stimulating agent utilization and cost considerations of chronic kidney disease patients not on dialysis**

*Abstract:* Value in Health. 2010 May; 13(3):A77. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)  
*Authors:* Vekeman F, Bailey RA, Laliberté F, Senbetta M, McKenzie RS, Lefebvre P

**Erythropoiesis-stimulating agent dosing and hemoglobin trends over time in chronic kidney disease patients not on dialysis**

*Abstract:* Value in Health. 2010 May; 13(3):A81. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)  
*Authors:* Lafeuille MH, Bailey RA, Laliberté F, Senbetta M, Vekeman F, McKenzie RS, Dea K, Lefebvre P

**Assessment of recent erythropoiesis-stimulating agent guidelines changes on dosing patterns in chronic kidney disease patients not on dialysis**

*Abstract:* Value in Health. 2010 May; 13(3):A81. ISPOR 15th Annual International Meeting, Atlanta, Georgia, USA, 15-19 May, 2010 (Poster)  
*Authors:* Lafeuille MH, Bailey RA, Laliberté F, Senbetta M, Vekeman F, McKenzie RS, Blacksmith A, Lefebvre P

**Patterns of treatment with angiogenesis inhibitors in patients with metastatic renal cell carcinoma (mRCC) in France**

*Abstract:* J Clin Oncol. 2010; 28(supp). American Society of Clinical Oncology (ASCO) 2010 Annual Meeting, Chicago, Illinois, 4-8 June, 2010 (Poster)  
*Authors:* Levy A, Gross-Goupil M, Sarda SP, Korves C, Antràs L, Luka A, Ramamurthy P, Neary M, Duh MS, Escudier B

**Costs of treatment with angiogenesis inhibitors (AIs) in patients with metastatic renal cell carcinoma (mRCC): results from a medical chart review study**

*Abstract:* Value in Health. 2010 May; 13(3):A32. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)  
*Authors:* Oh WK, McDermott DF, Duh MS, Antràs L, Chen K, Sarda SP, Luka A, Whittemore S, Ramamurthy P, Neary MP, Choueiri TK

**Health care costs associated with angiogenesis inhibitors (AIs) and mTOR inhibitors (mTORs) in patients with metastatic renal cell carcinoma (mRCC) treated at U.S. community oncology clinics**

*Abstract:* Value in Health. 2010 May; 13(3):A33. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)  
*Authors:* Chen K, Antràs L, Whittemore S, Luka A, Ramamurthy P, Scott J, Fortner B, Neary MP, Duh MS, Jolly P

**Health care costs associated with multikinase inhibitors (MKIs) for treatment of metastatic renal cell carcinoma (mRCC) in a clinical practice setting in Italy**

*Abstract:* Value in Health. 2010 May; 13(3):A33. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)  
*Authors:* Paglino C, Porta C, Canipari C, Antràs L, Chen K, Whittemore S, Luka A, Ramamurthy P, Neary MP, Duh MS

**Incidence and cost of adverse events (AEs) in patients with renal cell carcinoma (RCC) treated with angiogenesis inhibitors (AIs)**

*Abstract:* Value in Health. 2010 May; 13(3):A76. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Dial E, Duh MS, Antràs L, Rodermund D, Neary MP, Choueiri TK, Oh WK

**NEUROLOGICAL DISORDERS**

**Economic burden of epilepsy among the privately insured in the U.S.**

*Publication:* Pharmacoeconomics. 2010 Aug 1; 28(8):675-85.

*Authors:* Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Caleo S

**Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States**

*Publication:* Epilepsia. 2010 May; 51(5):838-44. Epub 2009 Dec 7.

*Authors:* Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Caleo S

**Generic antiepileptic drugs and associated medical resource utilization in the United States**

*Publication:* Neurology. 2010 May 18; 74(20):1566-74. Epub 2010 Apr 14.

*Authors:* Labiner DM, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Latremouille-Viau D, Lefebvre P, Helmers SL

**The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence**

*Publication:* Expert Opin Pharmacother. 2009 Oct; 10(14):2317-28. Review.

*Authors:* Duh MS, Cahill KE, Paradis PE, Crémieux PY, Greenberg PE

**Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study**

*Publication:* Epilepsia. 2009 Mar; 50(3):501-9. Epub 2008 Oct 3.

*Authors:* Faught RE, Weiner JR, Guérin A, Cunnington MC, Duh MS

**Interpretation of the weight matrix in an artificial neural network**

*Publication:* Am J Epidemiol. 1998; 147: 1112-22

*Authors:* Duh MS, Walker AM, Ayanian JZ

**Epidemiologic interpretation of artificial neural networks**

*Publication:* Am J Epidemiol. 1998 Jun 15; 147(12):1112-22.

*Authors:* Duh MS, Walker AM, Ayanian JZ

**Prediction and cross-validation of neural networks versus logistic regression: using hepatic disorders as an example**

*Publication:* Am J Epidemiol. 1998 Feb 15; 147(4):407-13.

*Authors:* Duh MS, Walker AM, Pagano M, Kronlund K

**The effectiveness of surgery on the treatment of acute spinal cord injury and its relationship with pharmacological treatment**

*Publication:* Neurosurgery 35:240-249, 1994

*Authors:* Duh MS, Shepard MJ, Wilberger JE, Bracken MB

**Uncontrolled epilepsy in a Medicaid population**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Mishagina N, Parisé H, Rovba L, Lefebvre P, Faught E

**Assessment of Parkinson's disease progression rates by stage of disease**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Johnson SJ, Kaltenboeck A, Diener MD, Tarrant ML, Birnbaum HG

**Impact of vague nerve stimulation (VNS) therapy on clinical outcomes and costs in Medicaid patients with drug-resistant epilepsy**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Duh MS, Faught E, Guérin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD

**Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis**

*Abstract:* Value in Health. 2010 May; 13(3):A140-1. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Ivanova JI, Phillips AL, Bergman RE, Birnbaum HG, Stewart M, Meletiche DM

**Economic value of lidocaine patch 5% vs. gabapentin or pregabalin in Medicaid patients with post herpetic neuralgia**

*Abstract:* Value in Health. 2010 May; 13(3):A206. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster). Journal of Managed Care Pharmacy. 2010 Mar; 16(2):149. Academy of Managed Care Pharmacy (AMCP) 22nd Annual Meeting & Showcase, San Diego, California, 7-10 April, 2010 (Poster)

*Authors:* Ivanova JI, Puenpatom RA, Kirson NY, Birnbaum HG, Wei R, Kantor E, Summers K

**Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%**

*Abstract:* Journal of Medical Economics. 2010; 13(3):472-81. American Pain Society's 29th Annual Scientific Meeting, Baltimore, MD, 6-8 May, 2010 (Poster)

*Authors:* Kirson N, Ivanova J, Birnbaum H, Wei R, Kantor E, Puenpatom A, Ben-Joseph R, Summers K

**Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis**

*Abstract:* 62nd American Academy of Neurology (AAN) Annual Meeting, Toronto, Ontario, Canada, 10-17 April, 2010 (Poster)

*Authors:* Phillips A, Ivanova J, Bergman R, Birnbaum H, Stewart M, Meletiche D

**OBESITY, METABOLIC, AND NUTRITIONAL DISORDERS**

**The impact of bariatric surgery on comorbidities and medication use among obese patients**

*Publication:* Obesity Surgery. 2010 Jul; 20(7):861-870.

*Authors:* Crémieux PY, Ledoux S, Clerici C, Crémieux F, Buessing M

**Economic effect of the clinical impact of bariatric surgery on morbidly obese patients with diabetes**

*Abstract:* American Society for Healthcare Engineering (ASHE) 47th Annual Conference, Tampa, Florida, 11-14 July, 2010 (Presentation)

*Authors:* Ghosh A, Crémieux PY, Klein S, Eapen S, McGavock T

**ONCOLOGY**

**Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials**

*Publication:* CMRO 2011 in press

*Authors:* Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A, Bollu VK, Williams D, Wei LJ, DeAngelo DJ

**Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy**

*Publication:* BMC Cancer. 2011 Mar 24;11(1):105.

*Authors:* Porta C, Paglino C, Imarisio I, Canipari C, Chen K, Neary M, Duh MS

**The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the U.S. Veterans Affairs population**

*Publication:* Prostate Cancer Prostatic Dis. 2011

Mar;14(1):79-84. Epub 2010 Dec 21

*Authors:* Velde NV, Wu EQ, Guo A, Lu M, Yu AP, Sharma H, Liu J, Fan CP, Shi L

**Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia**

*Publication:* Curr Med Res Opin. 2010 Dec;26(12):2861-9. Epub 2010 Nov 9

*Authors:* Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD

**Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study**

*Publication:* Urol Oncol. 2010 Oct 4.

*Authors:* Choueiri TK, McDermott D, Duh MS, Sarda SP, Neary MP, Oh WK

**Tolerability, efficacy, and safety of pegylated liposomal doxorubicin in combination with carboplatin versus gemcitabine-carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review**

*Publication:* The Oncologist. Oct 2010.

*Authors:* Holloway RW, Grendys EC, Lefebvre P, Vekeman F, McMeekin S

**Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma**

*Publication:* Urol Oncol. 2010 May 5.

*Authors:* Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antras L, Chen K, Duh MS, Jayawant SS, Oh WK, Atkins MB, Choueiri TK

**Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients**

*Publication:* Curr Med Res Opin. 2010 Jan; 26(1):61-9.

*Authors:* Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J

**Drug utilization and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database**

*Publication:* J Med Econ. 2009; 12(1):1-8

*Authors:* Vekeman F, McKenzie RS, Bookhart BK, Laliberté F, Duh MS, Piech CT, Lefebvre P

**Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review**

*Publication:* Support Care Cancer. 2009.

*Authors:* Diel IJ, Weide R, Köppler H, Antràs L, Smith M, Green J, Wintfeld N, Neary M, Duh MS

**Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review**

*Publication:* BJU Int. 2009 Oct 26.

*Authors:* Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, Shah K, Percy AG, Antràs L, Jayawant SS, Chen K, Wang ST, Luka A, Neary MP, McDermott D, Oh WK

**Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia**

*Publication:* Cancer. 2009 Oct 15.

*Authors:* Heaney ML, Toy EL, Vekeman F, Laliberté F, Dority BL, Perlman D, Barghout V, Duh MS

**Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis**

*Publication:* Curr Med Res Opin. 2009 Aug.

*Authors:* Duh MS, Dial E, Choueiri TK, Fournier AA, Antràs L, Rodermund D, Neary MP, Oh WK

**Symptom assessment in relapsed small cell lung cancer: cross-validation of the patient symptom assessment in lung cancer instrument**

*Publication:* J Thorac Oncol. 2008 Oct; 3(10):1137-45.

*Authors:* Chen L, Antràs L, Duh MS, Neary MP, O'Brien ME

**Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis**

*Publication:* Curr Med Res Opin. 2008 Feb.

*Authors:* Duh MS, Weiner JR, Lefebvre P, Neary MP, Skarin AT

**Psychometric validation of the patient symptom assessment in lung cancer instrument for small cell lung cancer**

*Publication:* Curr Med Res Opin. 2007 Nov; 23(11):2741-52.

*Authors:* Chen L, Antràs L, Duh MS, Levy N, Neary MP, O'Brien ME, von Pawel J

**Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients**

*Publication:* Value in Health. 2007 Sep-Oct; 10(5):408-14.

*Authors:* Wu EQ, Mulani P, Farrell MH, Sleep D

**Dose and cost comparison of erythropoietic agents in the inpatient hospital setting**

*Publication:* Am J Health Syst Pharm. 2007 Sep 15; 64(18):1943-9.

*Authors:* Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, Duh MS

**The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid**

*Publication:* Cancer. 2007 Mar; 109(6):1090-6.

*Authors:* Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antràs L, Smith M, Neary MP, Duh MS

**Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations**

*Publication:* Curr Med Res Opin. 2006 Jul; 22(9):1623-31.

*Authors:* Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS

**Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors**

*Publication:* Clin Breast Cancer. 2006 Jun; 7(2):127-32.

*Authors:* Mincey BA, Duh MS, Thomas SK, Moynour E, Marynchencko M, Boyce SP, Mallett D, Perez EA

**Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer**

*Publication:* J Urol. 2006 Jan; 175(1):136-9.

*Authors:* Smith MR, Boyce SP, Moynour E, Duh MS, Raut MK, Brandman J

**Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve**

*Publication:* The Oncologist 2005; 10: 438-448

*Authors:* Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ

**Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population**

*Publication:* Women's Health Issues. 2005 May-Jun; 15(3):97-108.

*Authors:* Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D

**The costs of cancer: cancer-related conditions can add dramatically to overall costs of care**

*Publication:* J Managed Care Med. 2002; 6(1):12-9.

*Authors:* Crémieux PY, Slavin MB, Fendrick AM, Hiriak T, Kosicki G

**The costs of cancer to a major employer in the United States: a case-control analysis**

*Publication:* Am J Manag Care. 2000 Nov; 6(11):1243-51.

*Authors:* Barnett A, Birnbaum H, Crémieux PY, Fendrick AM, Slavin MB

**Cost of outpatient blood transfusion in cancer patients**

*Publication:* J Clin Oncol. 2000 Jul; 18(14):2755-61.

*Authors:* Crémieux PY, Barrett B, Anderson K, Slavin MB

**Understanding the pharmacoeconomic profile of cancer**

*Publication:* ONE: Oncology Economics. 2000;

1(10):36-9.

*Authors:* Crémieux PY, Birnbaum HG, Greenberg PE

**Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anemia**

*Publication:* PharmacoEconomics. 1999 Nov; 16(5 Pt 1):459-72.

*Authors:* Crémieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB

**New methods to adjust for selective crossover in survival analysis: in assessments of cost-effectiveness of cancer therapies**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Workshop)

*Authors:* Delea TE, Duh MS, Wei LJ, Robins J

**Real world clinical resource utilization of metastatic prostate cancer patients in the United States: results from two large claims databases**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Senbetta M, Lafeuille MH, Dean J, McKenzie RS, Lefebvre P

**Treatment patterns and healthcare resource utilization of metastatic prostate cancer patients by physician specialty**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Senbetta M, Lafeuille MH, Dean J, McKenzie RS, Lefebvre P

**Patterns of angiogenesis inhibitor treatment in patients with metastatic renal cell carcinoma in Ireland**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* McDermott R, Donnellan P, McCaffrey J, Keane F, Sarda SP, Korves C, Luka A, Wei R, Neary MP, Hanley R, Duh MS

**Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma in United Kingdom**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)  
*Authors:* Hawkins R, Wagstaff J, Nathan P, Sarda SP, Vekeman F, Korves C, Dasgupta S, O'Mara S, Fitton S, Hayners J, Tham C, Wei R, Luka A, Neary MP, Duh MS

**Health care resource utilization and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)  
*Authors:* Le TK, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ

**Transfusional Iron Overload (TIO) monitoring and treatment: findings from an electronic medical records review study at the Moffitt Cancer Center and Research Institute**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)  
*Authors:* Du MS, Wetzstein GA, Guo A, Sasane M, Sarda SP, Korves C, Wang ST, Wei R, Clinton B, Ray LA

**The cost-effectiveness of bortezomib plus melphalan and prednisone versus lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment for the initial treatment of multiple myeloma in the United States**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)  
*Authors:* Wang ST, Huang H, Ba-Mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, Velde H, Duh MS

**Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia**

*Abstract:* 2010 Annual Meeting of the American Society of Hematology, Orlando, FL (Poster)  
*Authors:* Guerin A, Bollu V, Guo A, Griffin JD, Yu AP, Wu EQ

**The economic burden of pleural effusions (PE) in patients with chronic myeloid leukemia (CML)**

*Abstract:* 2010 Annual Meeting of the American Society of Hematology, Orlando, FL (Poster)  
*Authors:* Wu EQ, Guerin A, Bollu V, Williams D, Guo A, Ponce de Leon D, Yu AP, Quintas-Cardama A

**Healthcare costs of second-line (2L) metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BV) versus cetuximab (CX)**

*Abstract:* Annals of Oncology. 2010 Oct; 21(supp 8):viii342. 35th European Society for Medical Oncology Congress, Milan, Italy, 8-12 October, 2010 (Poster)  
*Authors:* Yim Y, Wu EQ, Yu AP, Yang H, Yu E

**Comparing early intervention with zoledronic acid to no biophosphonate (BP) therapy in patients with metastatic prostate cancer to bone: a study of the U.S. Veterans Affairs (VA) population**

*Abstract:* Cancer-Induced Bone Disease (CABS) 10th International Meeting, Sheffield, UK, 22-25 September, 2010 (Poster)  
*Authors:* Wu EQ, Guo A, Shi L, Lu M, Yu AP, Sharma H, Fan CPS, Vander Velde N

**Patterns of treatment with angiogenesis inhibitors in patients with metastatic renal cell carcinoma (mRCC) in France**

*Abstract:* J Clin Oncol. 2010; 28(supp). American Society of Clinical Oncology (ASCO) 2010 Annual Meeting, Chicago, Illinois, 4-8 June, 2010 (Poster)  
*Authors:* Levy A, Gross-Goupil M, Sarda SP, Korves C, Antràs L, Luka A, Ramamurthy P, Neary M, Duh MS, Escudier B

**Comparison of healthcare resource utilization and costs between nilotinib and dasatinib as second line therapies in chronic myeloid leukemia (CML)**

*Abstract:* Value in Health. 2010 May; 13(3):A32. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)  
*Authors:* Wu EQ, Bollu V, Guo A, Guérin A, Tsaneva M, Williams D, Griffin JD

**Non-adherence to imatinib in chronic myeloid leukemia (CML) patients is associated with short- and long-term negative impacts on healthcare resource utilization and costs**

*Abstract:* Value in Health. 2010 May; 13(3):A32. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)  
*Authors:* Guérin A, Bollu V, Guo A, Wu EQ, Yu AP, Sirulnik LA, Griffin JD

**Costs to Medicare of treating chronic lymphocytic leukemia patients with alemtuzumab**

*Abstract:* Value in Health. 2010 May; 13(3):A32. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Lafeuille MH, Vekeman F, Kerrigan M, Wang ST, Duh MS

**Costs of treatment with angiogenesis inhibitors (AIs) in patients with metastatic renal cell carcinoma (mRCC): results from a medical chart review study**

*Abstract:* Value in Health. 2010 May; 13(3):A32. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Oh WK, McDermott DF, Duh MS, Anràs L, Chen K, Sarda SP, Luka A, Whittemore S, Ramamurthy P, Neary MP, Choueiri TK

**Health care costs associated with angiogenesis inhibitors (AIs) and mTOR inhibitors (mTORs) in patients with metastatic renal cell carcinoma (mRCC) treated at U.S. community oncology clinics**

*Abstract:* Value in Health. 2010 May; 13(3):A33. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Chen K, Anràs L, Whittemore S, Luka A, Ramamurthy P, Scott J, Fortner B, Neary MP, Duh MS, Jolly P

**Health care costs associated with multikinase inhibitors (MKIs) for treatment of metastatic renal cell carcinoma (mRCC) in a clinical practice setting in Italy**

*Abstract:* Value in Health. 2010 May; 13(3):A33. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Paglino C, Porta C, Canipari C, Anràs L, Chen K, Whittemore S, Luka A, Ramamurthy P, Neary MP, Duh MS

**Lower health care resource utilization associated with managing nilotinib related adverse events in chronic myeloid leukemia (CML) patients: evidence from a clinical practice setting study**

*Abstract:* Value in Health. 2010 May; 13(3):A33. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Guérin A, Bollu V, Williams D

**Incidence and cost of adverse events (AEs) in patients with renal cell carcinoma (RCC) treated with angiogenesis inhibitors (AIs)**

*Abstract:* Value in Health. 2010 May; 13(3):A76. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Dial E, Duh MS, Anràs L, Rodermund D, Neary MP, Choueiri TK, Oh WK

**Modeling the cost-effectiveness of bortezomib for the initial treatment of multiple myeloma in the United States**

*Abstract:* Value in Health. 2010 May; 13(3):A210. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Wang ST, Huang H, Shi H, Duh MS, Chen K, Chang E, Korves C, Dhawan R, Cakana A, van de Velde H, Esseltine DL, Garrison L

**OVERACTIVE BLADDER**

**Employees with overactive bladder: work loss burden**

*Publication:* J Occup Environ Med. 2005 May; 47(5):439-46.

*Authors:* Wu EQ, Birnbaum HG, Marynchenko M, Mareva M, Williamson T, Mallett D

**PAIN AND PRESCRIPTION OPIOIDS**

**Risk of hepatotoxicity-related hospitalizations among patients treated with opioid / acetaminophen combination prescription pain medications**

*Publication:* Pain Medicine. 2010; 11(11):1718-1725.

*Authors:* Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Latremouille-Viau D, Wei R, Stangle B, Lafeuille M-H, Michna E, Greenberg P

**Removal of opioid / acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications**

*Publication:* Pain Medicine. 2010; 11(3):369-378.

*Authors:* Michna E, Duh M, Korves C, Dahl J

**Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction**

*Publication:* Appl Health Econ Health Policy. 2009; 7(1):61-70.

*Authors:* White AG, Birnbaum HG, Rothman DB, Katz N

**Analytic models to identify patients at risk for prescription opioid abuse**

*Publication:* Am J Manag Care. 2009 Dec; 15(12):897-906.

*Authors:* White AG, Birnbaum HG, Schiller M, Tang J, Katz NP

**Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia**

*Publication:* Pain. 2009 Sep; 10(9):976-83. Epub 2009 Jun 24.

*Authors:* White LA, Robinson RL, Yu AP, Kaltenboeck A, Samuels S, Mallett D, Birnbaum HG

**Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss**

*Publication:* J Occup Environ Med. 2008 Jan; 50(1):13-24.

*Authors:* White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL

**Foundations of opioid risk management**

*Publication:* Clin J Pain. 2007 Feb; 23(2):103-18.

*Authors:* Katz NP, Adams EH, Benneyan JC, Birnbaum HG, Budman SH, Buzzeo RW, Carr DB, Cicero TJ, Gourlay D, Inciardi JA, Joranson DE, Kesslick J, Lande SD

**Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective**

*Publication:* Clin J Pain. 2006 Oct; 22(8):667-76.

*Authors:* Birnbaum HG, White AG, Reynolds JL, Greenberg PE, Zhang M, Vallow S, Schein JR, Katz NP

**Economic burden of illness for employees with painful conditions**

*Publication:* J Occup Environ Med. 2005 Sep; 47(9):884-92.

*Authors:* White AG, Birnbaum HG, Mareva MN, Henckler AE, Grossman P, Mallett DA

**Direct costs of opioid abuse in an insured population in the United States**

*Publication:* J Manag Care Pharm. 2005 Jul-Aug; 11(6):469-79.

*Authors:* White AG, Birnbaum HG, Mareva MN, Daher M, Vallow S, Schein J, Katz N

**Economic cost and epidemiological characteristics of patients with fibromyalgia claims**

*Publication:* J Rheumatol. 2003 Jun; 30(6):1318-25.

*Authors:* Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ

**Direct and indirect costs associated with Dupuytren's contracture**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Macaulay D, Ivanova J, Birnbaum H, Sorg R, Skodny P

**Real-world use of duloxetine for low back pain and chronic low back pain: treatment patterns, direct and indirect costs**

*Abstract:* Value in Health. 2010 May; 13(3):A126. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Johnstone B, Faries D, Risser R, Swindle R

**Risk of hepatotoxicity-related hospitalizations among patients treated with opioid / acetaminophen combination prescription pain medications**

*Abstract:* Pain Med. 2010 Nov; 11(11):1718-25.

International Conference on Pharmacoepidemiology & Risk Management, Brighton, England, 19-22 August, 2010 (Poster)

*Authors:* Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Latremouille-Viau D, Wei RS, Stangle BE, Lafeuille MH, Michna E, Greenberg PE

**Societal costs of opioid abuse, dependence, and misuse in the United States**

*Abstract:* Value in Health. 2010 May; 13(3):A111. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Birnbaum H, White A, Schiller M, Waldman T, Cleveland JM, Setnik BS, Pixton GC, Roland CL

**PRICING AND REIMBURSEMENT**

**The risks and costs of multiple-generic substitution of topiramate**

*Publication:* Neurology. 2010 Feb 23; 74(8):701-2; author reply 701-2.

*Authors:* Sethi NK, Torgovnick J, Sethi PK, Arsur E, Emmanuel Paradis P, Duh MS, Durkin MB, Wan GJ

**Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries**

*Publication:* Curr Med Res Opin. 2009 Jul; 25(7):1793-805.

*Authors:* Paradis PE, Latrémouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS

**Clinical consequences of generic substitution of lamotrigine for patients with epilepsy**

*Publication:* Neurology. 2008 May 27; 70(22 Pt 2):2179-86.

*Authors:* LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O

**Economic impact of generic substitution of lamotrigine: projected costs in the U.S. using findings in a Canadian setting**

*Publication:* Curr Med Res Opin. 2008 Apr; 24(4):1069-81.

*Authors:* LeLorier J, Duh MS, Paradis PE, Latrémouille-Viau D, Lefebvre P, Manjunath R, Sheehy O

**The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine**

*Publication:* Dis Manag. 2007 Aug; 10(4):216-25.

*Authors:* Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Crémieux PY

**Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes**

*Publication:* Epilepsia. 2007 Mar; 48(3):464-9.

*Authors:* Andermann F, Duh MS, Gosselin A, Paradis PE

**Panel discussion: New imperatives for evidence to support successful licensing, reimbursement, and commercial strategy**

*Conference:* BIO International Convention, Chicago, IL, 6 May, 2010

*Panelists:* Chawla A (moderator), Szela M, Blansett L, Garrison L, Schroeder T

## RESPIRATORY DISEASE

**Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costs**

*Publication:* Respir Med. 2011 Mar; 105(3):435-41. Epub 2010 Sep 29.

*Authors:* Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS

**The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review**

*Publication:* COPD. 2010 Jun; 7(3):214-28

*Authors:* Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS

**Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin**

*Publication:* Curr Med Res Opin. 2010 Feb; 26(2):355-63

*Authors:* Signorovitch JE, Duh MS, Sengupta A, Gu A, Grant R, Raut M, Mody SH, Schein J, Fisher AC, Ng D

**Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone / budesonide and formoterol / salmeterol**

*Publication:* Clin Ther. 2009 Dec; 31(12):2779-803.

*Authors:* Frois C, Wu EQ, Ray S, Colice GL

**Costs and resource use of mild persistent asthma patients initiated on controller therapy**

*Publication:* J Asthma. 2008 May; 45(4):293-9.

*Authors:* Colice GL, Yu AP, Ivanova JI, Hsieh M, Birnbaum HG, Lage MJ, Brewster C

**Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature**

*Publication:* Expert Opin Pharmacother. 2008 Apr; 9(5):751-66.

*Authors:* Weiner JR, Toy EL, Sacco P, Duh MS

**Use of inhaled corticosteroids and healthcare costs in mild persistent asthma**

*Publication:* J Asthma. 2007 Jul-Aug; 44(6):479-83.

*Authors:* Colice GL, Wu EQ, Birnbaum HG, Daher M, Marynchenko MB

**Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study**

*Publication:* Crit Care. 2007 Jun 6; 11(3):R63.

*Authors:* Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, Shorr AF

**Development of a COPD severity score**

*Publication:* Curr Med Res Opin. 2006; 22(9):1679-87.

*Authors:* Wu EQ, Birnbaum HG, Cifaldi M, Kang YJ, Mallett D, Colice GL

**Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population**

*Publication:* J Occup Environ Med. 2006 Aug; 48(8):794-802.

*Authors:* Colice GL, Wu EQ, Birnbaum HG, Daher M, Marynchenko MB, Varghese S

**Treatment costs of community-acquired pneumonia in an employed population**

*Publication:* Chest. 2004 Jun; 125(6):2140-5.

*Authors:* Colice GL, Morley MA, Asche C, Birnbaum HG

**CRIT Study Group. Red blood cell transfusion and ventilator-associated pneumonia: a potential link?**

*Publication:* Crit Care Med. 2004 Mar; 32(3):666-74.

*Authors:* Shorr AF, Duh MS, Kelly KM, Kollef MH

**Lower respiratory tract infections: impact on the workplace**

*Publication:* Pharmacoeconomics. 2003; 21(10):749-59.

*Erratum in:* Pharmacoeconomics. 2003; 21(12):883.

*Authors:* Birnbaum HG, Morley M, Leong S, Greenberg PE, Colice GL

**Economic burden of respiratory infections in an employed population**

*Publication:* Chest. 2002 Aug; 122(2):603-11.

*Authors:* Birnbaum HG, Morley M, Greenberg PE, Colice GL

**Direct and indirect costs of asthma to an employer**

*Publication:* J Allergy Clin Immunol. 2002

Feb;109(2):264-70.

*Authors:* Birnbaum HG, Berger WE, Greenberg PE, Holland M, Auerbach R, Atkins KM, Wanke LA

**Economic burden of pneumonia in an employed population**

*Publication:* Arch Intern Med. 2001 Dec 10-24;

161(22):2725-31.

*Authors:* Birnbaum HG, Morley M, Greenberg PE, Cifaldi M, Colice GL

**Lack of intraocular pressure effect of budesonide inhalation therapy in a mixed asthmatic population**

*Publication:* Annals of Asthma, Allergy & Immunology. 2000; 85: 356-61.

*Authors:* Duh MS, Walker AM, Lindmark B, Laties AM

**Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis**

*Publication:* Clin Ther. 2000 Jan; 22(1):140-51.

*Authors:* LeLorier J, Perreault S, Birnbaum HG, Greenberg PE, Sheehy O

**Use of inhaled tobramycin is associated with reduced mortality in patients with cystic fibrosis**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, USA, 21-25 May, 2011;

The 24th Annual North American Cystic Fibrosis Conference, Baltimore, Maryland, 21-23 October, 2010 (Poster)

*Authors:* Signorovitch J, Sawicki GS, Zhang J, Latremouille-Viau D, Wu EQ, von Wartburg M, Lizabeth S

**Concomitant asthma medication use in patients using omalizumab: results from three large insurance claims databases**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Lefebvre P

**Persistence and adherence in patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs. single long-acting inhalers**

*Abstract:* Chest. 2010 Oct; 138(4):482A. American College of Chest Physicians CHEST 2010 Meeting, Vancouver, BC, Canada, 30 October-4 November, 2010 (Poster)

*Authors:* Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI

**Risk of exacerbations among patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs. single long-acting inhalers**

*Abstract:* Chest. 2010 Oct; 138(4):478A. American College of Chest Physicians CHEST 2010 Meeting, Vancouver, BC, Canada, 30 October-4 November, 2010 (Poster)

*Authors:* Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI

**Resource utilization and costs in patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs. single long-acting inhalers**

*Abstract:* Chest. 2010 Oct; 138(4):485A. American College of Chest Physicians CHEST 2010 Meeting, Vancouver, BC, Canada, 30 October-4 November, 2010 (Poster)

*Authors:* Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, Xie J, Wu EQ, Setyawan J, Dembiski M, Blum SI

**Comparison of drug costs and clinical outcomes with tobramycin solution for inhalation and aztreonam lysine for inhalation in cystic fibrosis**

*Abstract:* The 24th Annual North American Cystic Fibrosis Conference, Baltimore, Maryland, 21-23 October, 2010 (Poster)

*Authors:* Signorovitch J, Latremouille-Viau D, Dea K, Wu E, Zhang J

**Economic burden of exacerbations in chronic obstructive pulmonary disease**

*Abstract:* Value in Health. 2010 May; 13(3):A198. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Yu A, Yang H, Wu EQ, Dembiski M, Blum S, Setyawan J

**Relationship between daily dosing frequency, compliance, healthcare resource use, and costs: Evidence from the treatment of chronic obstructive pulmonary disease (COPD)**

*Abstract:* Value in Health. 2010 May; 13(3):A201. ISPOR 15th Annual International Meeting, Atlanta, Georgia, 15-19 May, 2010 (Poster)

*Authors:* Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat C, Swensen A, Duh MS

**Cost comparison among moderate or severe persistent asthma patients with and without asthma exacerbations**

*Abstract:* American Journal of Respiratory and Critical Care Medicine. 2010; 181:A3126. [American Thoracic Society International Convention, New Orleans, LA, 14-19 May, 2010 (Poster)]

*Authors:* Ivanova J, Bergman R, Birnbaum H, Colice G, Silverman R, McLaurin K

## RHEUMATOLOGY

**Societal cost of rheumatoid arthritis patients in the U.S.**

*Publication:* Curr Med Res Opin. 2010 Jan; 26(1):77-90.

*Authors:* Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M

**Employer model of workplace impacts of anti-TNF therapy for rheumatoid arthritis**

*Publication:* J Occup Environ Med. 2009 Oct; 51(10):1167-76.

*Authors:* Birnbaum H, Pike C, Kaufman R, Cifaldi M

**Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature**

*Publication:* Expert Opin Pharmacother. 2009 Feb; 10(2):255-69. Review.

*Authors:* Birnbaum H, Shi L, Pike C, Kaufman R, Sun P, Cifaldi M

**Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States**

*Publication:* J Occup Environ Med. 2008 Sep; 50(9):998-1005.

*Authors:* White AG, Birnbaum HG, Janagap C, Buteau S, Schein J

**Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis**

*Publication:* Curr Med Res Opin. 2008 Aug; 24(8):2229-40.

*Authors:* Wu EQ, Chen L, Birnbaum HG, Yang E, Cifaldi M

**Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data**

*Publication:* Curr Med Res Opin. 2007 Aug; 23(8):1749-59.

*Authors:* Wu EQ, Chen L, Birnbaum HG, Yang E, Cifaldi M

**Direct and indirect costs of rheumatoid arthritis to an employer**

*Publication:* J Occup Environ Med. 2000 Jun; 42(6):588-96.

*Authors:* Birnbaum HG, Barton M, Greenberg PE, Sisitsky T, Auerbach R, Wanke LA, Buatti MC

**Indirect comparison of adalimumab vs. etanercept for the treatment of psoriatic arthritis**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi MA

**Direct and indirect costs of spondyloarthritis patients pre- and post-diagnosis**

*Abstract:* American College of Rheumatology/Association of Rheumatology Health Professionals 74th Annual Scientific Meeting, Atlanta, Georgia, 7-11 November, 2010 (Poster)

*Authors:* Kirson N, Birnbaum HG, Rao S, Swallow KE, Waldman T, Dayoub E, Cifaldi M

**Diagnostic and resource use profiles before and after diagnosis of spondyloarthritis**

*Abstract:* Ann Rheum Dis. 2010; 69(suppl 3):470. European League Against Rheumatism (EULAR) 2010 Congress, Rome, Italy, 16-19 June, 2010 (Poster)

*Authors:* Kirson N, Birnbaum H, Rao S, Swallow K, Waldman T, Dayoub E, Cifaldi M

**Racial differences in use of biologics for Crohn's disease in a Medicaid population**

*Abstract:* American College of Gastroenterology Annual Scientific Meeting, San Antonio, Texas, 15-20 October, 2010 (Poster)

*Authors:* Flasar M, Mulani P, Yang M, Chao J, Lu M, Cross R

**WOMEN'S HEALTH****Annual costs associated with diagnosis of uterine leiomyomata**

*Publication:* Obstet Gynecol. 2006 Oct; 108(4):930-7.

*Authors:* Hartmann KE, Birnbaum HG, Ben-Hamadi R, Wu EQ, Farrell MH, Spalding J, Stang P

**A retrospective claims database analysis to assess patterns of interstitial cystitis diagnosis**

*Publication:* Curr Med Res Opin. 2006 March; 22(3):495-500.

*Authors:* Wu EQ, Birnbaum HG, Kang YJ, Parece A, Mallett D, Taitel H, Evans RJ

**Assessing the economic impact of chronic conditions in postmenopausal women**

*Publication:* Expert Opin Pharmacother. 2005 Sep; 6(11):1803-14.

*Authors:* Sasser AC, Taylor M, Birnbaum HG, Schoenfeld MJ, Oster EF, Rousculp M

**Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population**

*Publication:* Women's Health Issues. 2005 May-Jun; 15(3):97-108.

*Authors:* Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D

**Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence**

*Publication:* Womens Health Issues. 2003 Nov-Dec; 13(6):204-13.

*Authors:* Birnbaum HG, Leong S, Kabra A

**Healthcare resource utilization and costs in females with newly diagnosed heavy menstrual bleeding: an employer's perspective**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Jensen JF, Lefebvre P, Laliberté F, Sarda SP, Law A, Pocoski J, Duh MS

**Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: estradiol transdermal system vs. oral estrogen-only hormone therapy**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)

*Authors:* Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P





## **ABOUT ANALYSIS GROUP**

**Analysis Group** provides health outcomes research and economic consulting to leading corporations and government agencies. The firm has 500 professionals, with offices in Boston, Chicago, Dallas, Denver, Los Angeles, Menlo Park, New York, San Francisco, Washington, and Montreal.



BOSTON CHICAGO DALLAS DENVER LOS ANGELES MENLO PARK MONTREAL NEW YORK SAN FRANCISCO WASHINGTON

[www.analysisgroup.com](http://www.analysisgroup.com)